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Glossary of Abbreviations 29 
 30 
AVR  aortic valve replacement  31 
mAVR  minimal access aortic valve replacement 32 
BMI  body mass index 33 
CI  95% confidence interval 34 
COPD  chronic obstructive pulmonary disease  35 
CPB  cardiopulmonary bypass 36 
FEV1   forced expiratory volume in one second 37 
FS  full median sternotomy 38 
HR  hazard ratio 39 
HRQoL health-related quality of life 40 
ICER  incremental cost-effectiveness ratio 41 
LVEF  left ventricular ejection fraction  42 
MS  mini-sternotomy 43 
NHS  National Health Service 44 
OR  odds ratio  45 
QALY  quality-adjusted life year 46 
RCT  randomised control trial  47 
SAE   serious adverse event 48 
SD  standard deviation 49 
TLCO   transfer factor of the lung for carbon monoxide 50 
TOE  transoesophageal echocardiogram 51 
UK  United Kingdom 52 
  53 
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Central Message 54 
 55 
In the UK NHS, compared to conventional median sternotomy approach for surgical AVR, 56 
mini-sternotomy did not hasten recovery or hospital discharge, and was not cost-effective.   57 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
 
5 
 
Perspective Statement 58 
Minimal access surgery is appealing for its perceived advantages including better patient 59 
recovery, satisfaction and cost-effectiveness.  This RCT conducted within the UK NHS 60 
setting did not demonstrate quicker patient recovery or cost-effectiveness associated with 61 
mini-sternotomy compared to full median sternotomy approach.  These findings are relevant 62 
to physicians, patients and health care funders.  63 
64 
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Structured Abstract 65 
Objective:  Aortic valve replacement (AVR) can be performed either through full median 66 
sternotomy (FS) or upper mini-sternotomy (MS).  The Mini-Stern trial aimed to establish 67 
whether MS leads to quicker postoperative recovery and shorter hospital stay after first-time 68 
isolated AVR.   69 
Methods:   This pragmatic, open-label, parallel RCT compared MS with FS for first-time 70 
isolated AVR in two UK NHS hospitals. Primary endpoints were duration of postoperative 71 
hospital stay and the time to fitness for discharge from hospital after AVR, analysed in the 72 
intent-to-treat population.  73 
Results:  In this RCT, 222 patients were recruited and randomised (118 MS, 104 FS).    74 
Compared to FS patients, MS patients had longer hospital stay (mean 9.5 vs. 8.6 days) and 75 
took longer to achieve fitness for discharge home (mean 8.5 vs. 7.5 days). Adjusting for valve 76 
type, sex and surgeon, hazard ratios (HR) from Cox models did not show a statistically 77 
significant effect of MS (relative to FS) on either hospital stay (HR 0.874, 95% CI 0.668-78 
1.143, p-value 0.3246) or time to fitness for discharge (HR 0.907, 95% CI 0.688-1.197, p-79 
value 0.4914).  During mean follow up of 760 days (MS:745 and FS:777 days), 12 (10%) MS 80 
and 7 (7%) FS patients died (HR 1.871, 95% CI 0.723-4.844, p-value 0.1966). Average extra 81 
cost for MS was £1,714, during the first 12 months after AVR.  82 
Conclusions:  Compared to FS for AVR, MS did not result in shorter hospital stay, faster 83 
recovery or improved survival and was not cost-effective.  MS approach is not superior to FS 84 
for performing AVR. 85 
Word count for Abstract:  248  86 
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Introduction 87 
Aortic valve replacement (AVR) is the second commonest cardiac surgery in the UK [1] with 88 
an increasing proportion of older patients [1, 2].  Minimal access AVR (mAVR) might 89 
shorten hospital stay and postoperative recovery period and could be beneficial if offered 90 
safely and cost-effectively.   91 
 92 
Currently, most AVRs are performed safely through full median sternotomy (FS) [2-6].  93 
However, mAVR may be associated with less postoperative pain, blood loss, pulmonary and 94 
wound complications and shorter hospital stay [2]. The most commonly practised mAVR 95 
involves mini-sternotomy (MS), which could potentially hasten postoperative recovery, 96 
shorten hospital stay and improve patient satisfaction [2-10]. 97 
 98 
Most studies comparing MS and FS for AVR are non-randomised.  Although systematic 99 
reviews with meta-analyses [11, 12] have been conducted, inadequate statistical power and 100 
heterogeneity of studies calls for prospective, randomised control trials (RCTs) to assess 101 
benefits and risks of mAVR.  Published evidence on cost-effectiveness comparing MS to FS 102 
is sparse and weak. A recent review comparing cost-effectiveness of FS and MS called for a 103 
well-designed RCT to evaluate cost-effectiveness of mAVR up to at least a year after surgery 104 
[13]. Recently, a propensity-matched study from the UK national data concluded that mAVR 105 
is safe and was associated with shorter postoperative hospital stay [14]. The authors 106 
concluded that although general clinical equipoise exists between FS and MS, it is essential 107 
to have a well-constructed and adequately powered RCT before widespread adoption of MS.  108 
This retrospective study did not analyse cost-effectiveness of either surgical approach. 109 
 110 
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The Mini-Stern trial assessed whether MS is superior to FS in shortening postoperative 111 
recovery time and improving patient outcomes without compromising patient safety. It also 112 
assessed cost-effectiveness of MS from the perspective of the UK NHS as a health care 113 
provider. 114 
 115 
Materials and Methods 116 
Mini-Stern was a two-centre, pragmatic, open-label RCT conducted in the UK.  Patients were 117 
randomised (1:1) to AVR either by MS or FS.  118 
 119 
 Sample Size 120 
Considering four published RCTs [5, 6, 9, 10] and two cohort studies [7, 8], a 20% reduction 121 
in hospital stay from 11.7 to 9.36 days was considered clinically significant.  Based on an 122 
internal audit of 252 first-time elective AVRs performed at Papworth Hospital in 2007/08 123 
(mean hospital stay 11.7 days, SD 6.2), to detect this change with 80% power and 2-sided 124 
significance of 5%, 110 patients per group were required. As randomisation was performed 125 
on the day of surgery after induction of anaesthesia and introduction of the transoesophageal 126 
echocardiogram (TOE) probe, no subjects dropped out between randomisation and surgery 127 
thereby making the total trial recruitment target, 220 patients. 128 
 129 
Recruitment 130 
Adult patients undergoing first-time isolated AVR were included.  Exclusion criteria included 131 
emergency AVR, LVEF≤ 30%, chest wall deformities, severe COPD (FEV1 or TLCO < 40% 132 
predicted), BMI > 35kg/m2, concomitant cardiac surgery, redo-surgery and inability to 133 
perform TOE. Details of patient enrolment are given in the online protocol. 134 
 135 
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Randomisation 136 
Randomisation (1:1) used random permuted blocks of variable lengths (6 or 8), stratified by 137 
surgeon and valve prosthesis (bio-prosthetic or mechanical). Random allocations were pre-138 
generated, held in secure files by Papworth Trials Unit.  During early days of the trial, TOE 139 
probe could not be passed in four patients due to technical reasons.  These patients underwent 140 
the allocated procedure and were included in the trial. Later the Trial Steering Committee 141 
decided that under such circumstances, MS would be unsafe and patients should be excluded 142 
from the trial to FS.  Since eligibility for MS required TOE, in order to avoid post-143 
randomisation drop-out, group allocation for the study subjects was retrieved via telephone 144 
by theatre staff soon after anaesthesia and introduction of the TOE probe.  Due to the nature 145 
of interventions, this trial could not be blinded.  146 
 147 
Outcomes 148 
Primary endpoints:  Two closely related primary endpoints were measured.  Firstly, length 149 
of postoperative hospital stay (days between surgery and actual hospital discharge) which is 150 
easily measured, a surrogate for early postoperative events and sensitive to outcomes that 151 
affect health-related quality of life (HRQoL).  Secondly, the interval in days between surgery 152 
and the patient being medically fit for discharge. To reduce investigator bias, standard 153 
discharge criteria were followed to decide the day of fitness for discharge. This endpoint was 154 
chosen to address exogenous effects (social factors, lack of transport, non-availability of 155 
space in nursing homes etc.) that commonly delay hospital discharge in the UK. 156 
 157 
Clinical secondary endpoints: duration of surgery,  total theatre time,  aortic cross-clamp 158 
and cardiopulmonary bypass (CPB) times, blood loss in the first 12 hours after surgery,  159 
transfusion of blood and clotting products in the first 48 hours (blood transfusion trigger was 160 
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haemoglobin level < 80g/L),  frequency of re-intubation,  time to initial extubation, 161 
mediastinal drain removal and first independent mobilisation,  daily pain scores at rest and on 162 
deep breath (over the first ten days or until hospital discharge) on a scale of 0 to 10, LVEF 163 
and severity of para-prosthetic regurgitation at hospital discharge and at 6 months, and time 164 
to all-cause death. Definitions of adverse events and details of their reporting are in the online 165 
protocol.  To exclude bias, clinical outcome data were collected by research team  who were 166 
not involved in routine care of subjects, following standardised protocols.   167 
 168 
Non-clinical secondary endpoints:  Health-related Quality of Life and Healthcare resource 169 
use. 170 
HRQoL:  Patients completed EQ-5D-3L [15] and SF-36 [16, 17] questionnaires at baseline, 171 
6 weeks, 6 months and 12 months following surgery. EQ-5D-3L was repeated on fourth 172 
postoperative day and at discharge.   173 
Healthcare resource use:   Patient-specific resource use collected from hospital records and 174 
patient interviews during the primary admission included phases of care including operative 175 
surgery, critical care, post-surgical ward care and medications. Post-discharge resource use 176 
included attending wound clinics, community nurse visits, physiotherapy sessions, 177 
occupational therapy services, medical tests, cost of analgesics and other drugs and further 178 
hospitalisation within the first year after AVR. 179 
 180 
Surgical details 181 
All participating surgeons were consultants experienced in performing AVR by both FS and 182 
MS. They followed the operative surgical protocol as described below. 183 
MS approach: With the patient anaesthetised as per standard protocol, skin was incised from 184 
half-way between the suprasternal notch and the sternal angle to the level of the fourth 185 
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intercostal space, measuring approximately 8cm. The manubrium was divided in the midline 186 
from the suprasternal notch inferiorly and then into the right 4th intercostal space. Thymus 187 
was divided and pericardium opened exposing the ascending aorta, aortic root and right atrial 188 
appendage.  A loading dose of unfractionated heparin 300U/kg followed by boluses of 5000U 189 
was administered to achieve activated clotting time above 450 seconds.  Aorta was 190 
cannulated using a wired flexible aortic cannula. Right atrial appendage was cannulated using 191 
a flat venous cannula and CPB commenced.  The ascending aorta was cross-clamped and 192 
intermittent, antegrade, cold blood cardioplegia administered. The aorta was then incised 193 
open in an oblique or transverse fashion, the diseased valve excised and annulus decalcified.  194 
A suitably sized aortic valve prosthesis was inserted using either horizontal mattress, 2-0 195 
Ethibond sutures or semi-continuous, 2-0 Prolene sutures. Surgeons adopted either of these 196 
suture techniques and adhered to the same technique irrespective of the type of valve 197 
prosthesis or the surgical approach.  Aortotomy was then closed, heart de-aired, right atrial 198 
and ventricular epicardial pacing wires inserted and patient weaned off CPB.  After 199 
confirming satisfactory functioning of the aortic valve prosthesis by TOE, heparin was 200 
reversed with protamine (1mg/100U of heparin).  Chest drains were inserted into the anterior 201 
mediastinum, posterior pericardial space and pleural space if necessary.  Sternal wires were 202 
inserted and incision closed in layers. Conversion to FS was performed to ensure patient 203 
safety if access was difficult or if intraoperative complications occurred.    204 
 205 
FS approach:  Anaesthesia and positioning of patients was the same as for MS approach.  206 
The skin incision was made between the suprasternal notch and the xiphoid process and 207 
sternum divided in the midline from the suprasternal notch to the xiphoid process.  A two-208 
stage venous cannula was used for atrial cannulation.  Remaining steps were similar to MS 209 
approach. 210 
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 Statistical analysis 211 
Analyses of primary and secondary endpoints used intention-to-treat and included all 212 
randomised patients. Unless stated otherwise, statistical models included treatment (MS vs. 213 
FS), valve (mechanical vs. bio-prosthetic) and sex as fixed effects, and surgeons as random 214 
effects. Hypothesis testing was two-sided at the 5% significance level, with no adjustments 215 
for multiple testing. All confidence intervals (CI) were estimated at the 95% confidence level.  216 
Distributions of time-to-event endpoints were compared between study groups using Kaplan-217 
Meier curves and log-rank tests (stratified by sex, valve and surgeon). Hazard ratios (HR) for 218 
MS relative to FS were estimated from a Cox model. The null hypothesis of no treatment 219 
effect (HR = 1) was tested. Patients who were lost to follow-up, withdrew or died before the 220 
event were censored at the latest time they were known to be event-free. Models were 221 
checked by plotting Schoenfeld and deviance residuals.  For primary endpoints, Cox models 222 
were re-fitted using the per-protocol population and in sensitivity analyses (Appendix A. 223 
Table A4).   224 
Need for reintubation and other dichotomous endpoints were compared between groups by 225 
estimating a MS/FS odds ratio (OR) via logistic regression. EQ-5D, SF-36 and pain scores 226 
were modelled using repeated measures linear regression. Where possible, random intercepts 227 
and random time coefficients for patients were included. For EQ-5D and SF-36, fixed effects 228 
for baseline scores were included. Models were fitted using complete cases, then re-fitted 229 
with multiple imputation of missing scores via chained equations.  230 
Serious adverse events (SAEs) were analysed in the safety population according to 231 
intervention received. Patients randomised to MS who crossed over to FS prior to surgery 232 
were considered to have received FS; those who crossed over after MS had commenced were 233 
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considered to have received MS. Rates of SAEs were explored using Poisson regression with 234 
a random patient effect.     235 
 CONSORT guidelines [18] were followed. Analyses were performed in SAS version 9.4 236 
(SAS Institute Inc., Cary, NC, USA). No interim analyses were undertaken but reports were 237 
presented annually to the Data Monitoring and Ethics Committee.  238 
Economic analysis  239 
Unit costs were obtained from nationally published sources in the UK [19, 20, 21, 22] or 240 
from the Finance department, Papworth Hospital when the former did not provide the 241 
required information.  Total cost per patient was calculated by summing resource use items 242 
multiplied by unit costs across the in-patient stay and the 12-month postoperative follow-up 243 
period (Appendix B. Table B7). Health state utilities from the EQ-5D-3L and SF-36, based 244 
on UK value sets [15, 23] were used to generate quality-adjusted life years (QALYs) using 245 
the area under the curve method and assigning a value of zero from date of death.  Missing 246 
values were imputed using chained predictive mean matching, stratified by treatment and 247 
conditional on age, sex and baseline EQ-5D-3L. 248 
  249 
Differences in mean costs and QALYs were estimated using seemingly unrelated regression, 250 
controlling for age, sex, valve, baseline EQ-5D-3L and treatment, to accommodate skewness 251 
[24].  Uncertainty in cost-effectiveness was estimated by drawing 1000 bootstrapped samples 252 
and conducting probabilistic sensitivity analysis. Results are presented as incremental net 253 
monetary benefit at various thresholds of willingness to pay per QALY, cost-effectiveness 254 
planes and cost-effectiveness acceptability curves. Deterministic sensitivity analyses explored 255 
effects of using complete cases only, SF6D-based QALY estimates, the procedure inpatient 256 
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admission only, excluding patients who died and excluding additional equipment costs 257 
(Appendix B. Table B11).  258 
 259 
Results 260 
Overall 1024 patients were screened between 28 January 2010 and 13 April 2015, of whom 261 
222 were recruited and randomised to MS (118) or FS (104).  One-year follow-up was 262 
completed on 23 May 2016.  263 
Study groups were similar at baseline except for a non-significant sex imbalance (Table 1). In 264 
this trial, MS was not completed in 14 (12%) of 118 patients randomised to MS. Of these 265 
patients, 6 (5%) had conversion from MS to FS due to reasons listed in Figure 1. The 266 
remaining 8 patients underwent FS after randomisation to MS but without initial MS incision 267 
as MS was considered unsafe/impractical.  The true rate of intraoperative conversion of MS 268 
to FS was therefore 5%. Four patients (2%, Table 2) were censored before discharge: one 269 
withdrawal before surgery (FS) and three deaths (all randomised to and received MS). A 270 
further thirteen (6%) were censored before fitness for discharge: six discharged to acute 271 
hospital (three MS, three FS), seven to long-term care or rehabilitation (three FS, four MS). 272 
Mean time to hospital discharge was longer for MS than FS (9.5 vs. 8.6 days), as was mean 273 
time to fitness to discharge (8.5 vs. 7.5 days). However, distributions of these endpoints were 274 
similar in both groups (Figure 2, Table 2). The difference was not statistically significant in 275 
either primary analyses using Cox models (Figure 3), log-rank tests (Table 2) or sensitivity 276 
analyses (Appendix A. Table A4). The gamma-distributed frailty term in the Cox models was 277 
estimated to have variance 0.006675 for time to fitness and 0.000100 for time to discharge, 278 
suggesting that surgeon heterogeneity was negligible.  279 
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Time to drain removal (including drains inserted/retained to treat complications) was longer 280 
for MS, but times to extubation and independent mobilisation did not differ significantly 281 
between groups (Table 2, Figure 3), nor did numbers of patients re-intubated (six MS vs. five 282 
FS, OR 1.039, CI 0.306-3.531, p=0.9512). Statistically significant HRs indicated longer 283 
surgery, CPB, cross-clamp and theatre times for MS (Figure 3). No significant differences 284 
were seen in blood loss (Appendix A. Table A3), or in numbers of patients requiring 285 
transfusion of blood (50 MS vs. 51 FS, OR 0.797, CI 0.453-1.402, p=0.4310) or clotting 286 
products (11 MS vs 4 FS, OR 2.616, CI 0.801-8.541, p=0.1112). 287 
Regression models for pain at rest, EQ-5D utilities and SF-36 domain scores (Appendix A. 288 
Tables A6, A7, A8) estimated greater rate of improvement over time in MS patients for three 289 
SF-36 domains (social functioning, vitality and role physical). After multiple imputation, the 290 
difference was only significant for the role physical domain (Appendix A. Table A9). Pain on 291 
deep breath was not analysed as only less than half the data were collected due to poor patient 292 
compliance. 293 
 Nine (4%) patients died within a year of surgery: seven (6%) MS, two (2%) FS.  Five deaths 294 
were possibly related to treatment (four MS, one FS), none were probably or definitely 295 
related (Appendix A. Table A15). Overall, twelve (10%) MS and seven (7%) FS patients died 296 
during follow-up (mean follow-up 760 days: 745 MS, 777 FS).  Time to all-cause death, 297 
adjusted for age, showed a moderately large but statistically non-significant HR (MS/FS) of 298 
1.871 (CI 0.723-4.844, p=0.1966). 299 
Safety analyses excluded one patient who was withdrawn before surgery.  There were 300 
significantly more SAEs in MS recipients (rate ratio 1.615, CI 1.070-2.437, p=0.0225) 301 
(Appendix A. Table A11).  The numbers of patients experiencing SAEs were not 302 
significantly different (OR 1.559, CI 0.895-2.715, p=0.1161). Incidence of para-prosthetic 303 
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regurgitation did not differ significantly between groups (Appendix A. Table A13). Seven 304 
patients developed pericardial collection (three MS vs four FS, OR 0.680, CI 0.146-3.178, 305 
p=0.6229).  Wound infections (including superficial and deep infections) were more common 306 
in FS recipients (thirteen FS vs four MS, OR 0.312, CI 0.097-1.005, p=0.0511). Deep sternal 307 
wound infection developed in one MS and one FS recipient, neither of whom required plastic 308 
surgical repair.     309 
Economic analyses are summarised in Table 4. There was additional cost for MS relative to 310 
FS (£1,714 per patient, p=0.0765) in the first year following surgery. MS patients had (non-311 
significant) better EQ-5D-based QALYs (0.03 per patient, p=0.1509). The incremental cost 312 
per QALY gained was £61,379, but after adjusting for baseline characteristics, MS had 313 
higher costs and lower QALYs (i.e. was dominated).  In deterministic and probabilistic 314 
sensitivity analyses, MS was either dominated or had a very large cost per QALY, except for 315 
the complete case analysis (Appendix B. Tables B11, B12).  316 
Discussion 317 
The UK NHS is a free for patient at point-of-delivery healthcare system. Apart from good 318 
recovery, hospital discharge of a significant proportion of elderly patients depends on the 319 
timely availability of social care services in the community.  The Mini-Stern trial is the first 320 
RCT comparing FS and MS for isolated AVR when performed for UK NHS patients.   321 
 322 
In this prospective, pragmatic, open-label RCT, MS did not reduce the total duration of 323 
hospital stay after AVR.  As hospital discharge is sometimes delayed due to social factors, we 324 
included time until fit for discharge as a second primary endpoint.  This was also not reduced 325 
by MS. These endpoints were recorded by physiotherapists based on a common discharge 326 
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protocol with specific clinical milestones to achieve, thereby excluding physician-induced 327 
bias.  328 
 329 
In this study operation, total theatre, aortic cross-clamp and CPB times were significantly 330 
prolonged with MS. This was expected as in general, minimal access valve operations take 331 
longer [5, 9].  This is justifiable if MS resulted in either faster recovery, shorter postoperative 332 
stay, reduced cost of treatment or more importantly a significant reduction in adverse events 333 
and therefore superior patient safety.  In this RCT, MS did not achieve these benefits and 334 
hence we feel that the prolonged operation time, total theatre, cross-clamp and CPB times are 335 
not justifiable for performing AVR through MS.      336 
 337 
Previously, two meta-analyses [11, 12] concluded that mAVR approaches are superior in 338 
certain aspects of postoperative recovery. However, both included studies on mini-339 
thoracotomy approach for AVR, and therefore inferences drawn cannot be extrapolated to 340 
MS. A retrospective propensity-matched analysis of data from a UK national database 341 
concluded that MS is safe and comparable to conventional AVR [14]. The authors found that 342 
MS resulted in a shorter postoperative hospital stay, which disagrees with our findings.  343 
However, a propensity-matched study can suffer from selection bias if its matching algorithm 344 
produces treatment groups that are unbalanced in some unobserved characteristics.  Recently, 345 
a retrospective study demonstrated safety of right thoracotomy minimally invasive isolated 346 
and concomitant AVR in patients of all age groups [25].  As randomisation balances study 347 
groups in known and unknown characteristics, results of the Mini-Stern trial should be more 348 
reliable than non-randomised studies.   349 
 350 
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Previous studies investigating cost-effectiveness provided unclear answers.  A report 351 
analysing registry data from patients who underwent isolated primary AVR [26] reported 352 
lower hospital cost when AVR was performed through right anterior thoracotomy compared 353 
to sternotomy-based approaches with no significant differences in outcome. The main reasons 354 
attributed to lower costs were earlier hospital discharge and reduced use of blood products. 355 
Ghanta et al [27] noted that exclusion of rehabilitation costs could alter this finding. A review 356 
by Glauber et al [13], based on uncontrolled studies, noted that higher cost of instruments and 357 
devices in mAVR could be offset by economic advantage gained by  shorter hospital stay and 358 
lower complication rates.  The Mini-Stern trial assessed cost-effectiveness using a range of 359 
sensitivity analyses, but only the complete case analysis showed MS to be cost-effective, 360 
suggesting lower costs but slightly worse outcomes with MS.  However, this analysis used a 361 
potentially unrepresentative sample of just 90 patients.   Our analysis was restricted to the 362 
first year following operation without long-term analysis beyond 1 year. 363 
 364 
This RCT is robust with many merits including on-table randomisation, comprehensive and 365 
independent outcome assessment without physician-bias, longer-term clinical assessment, 366 
HRQoL analysis and economic analysis.  However there were some limitations. Although we 367 
report on secondary endpoints, this trial was powered only to address the primary endpoint.  368 
A total of 14 patients (12%) allocated to MS received FS, which could be another limitation.  369 
However, only 6 patients (5%) had true conversion after an attempted MS, while 8 patients 370 
(6.7%) went on to FS for safety reasons.  Although this RCT took place in only two centres, 371 
thereby limiting generalisability, recruitment by eight surgeons improves generalisability.  A 372 
total of 1024 patients were screened to recruit 222 (21.7%) patients.  Although this 373 
potentially suggests selection bias, only 125 eligible patients (12.2%) failed recruitment while 374 
the remaining 667 patients (65.1%) did not meet inclusion criteria.  Blinding was not 375 
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practical as sternotomy dressings were usually changed 48 hours after surgery and patients 376 
became aware of the approach.  This could have caused bias in self-reported outcomes. 377 
Missing ‘pain at rest’ data were unlikely to be missing at random, and therefore imputation 378 
might not have addressed all potential biases. Despite having two primary outcomes, we did 379 
not adjust for multiple testing.  However, as neither showed a significant difference between 380 
groups, this would not have affected our conclusions.   381 
 382 
In conclusion, MS for AVR did not result in quicker recovery or earlier hospital discharge.  383 
MS resulted in longer operations, increased costs, and resulted in more SAEs than FS. 384 
Overall, this pragmatic RCT did not provide evidence that MS results in better clinical or 385 
quality of life outcomes, or that MS is cost-effective compared to FS in the first year after 386 
AVR.  387 
 388 
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Legends 401 
Central Picture Legend:  Duration of hospital stay after AVR: FS versus MS. 402 
Video Legend: MS approach for AVR. 403 
Figure 1. Trial flow diagram.  404 
Figure 2. Kaplan-Meier curves for primary endpoints. Points indicate censoring and dashed 405 
lines represent 95% confidence intervals.  406 
Figure 3. Forest plot of HRs and 95% confidence intervals from Cox models.  407 
 Figure 4. Cost-effectiveness planes. Proportion of points below each threshold gives the 408 
probability that MS is more cost-effective than FS. This probability is 3.7% for willingness to 409 
pay £20,000/QALY and 5.1% for willingness to pay £30,000/QALY. 410 
 411 
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Table 1.   Baseline characteristics 412 
 MS (n = 118) FS (n = 104) 
Age (years) - Mean (SD) 71.3 (12.3) 72.1 (10.9) 
BMI (kg/m2) – Mean (SD) 26.6 (3.2) 27.7 (3.7) 
Sex - frequency (%)   
Female 53 (45%) 57 (55%) 
Male 65 (55%) 47 (45%) 
Valve type - frequency (%)   
Mechanical 15 (13%) 14 (13%) 
Tissue 103 (87%) 90 (87%) 
EuroSCORE (%) - Mean (SD) 5.9 (2.1) * 6.1 (2.1) 
* EuroSCORE was missing for one MS patient. 413 
 414 
 415 
 416 
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Table 2. Kaplan-Meier medians (quartiles) for time-to-event endpoints 417 
 MS (n = 118) FS (n = 104) p-value* 
Time to discharge (days) 7 (6, 10) 7 (6, 10)  0.6924 
Censored 3 1  
Time until fit for discharge (days) 6 (5, 10) 6 (5, 9) 0.5597 
Censored 10 7  
Time to independent mobilisation (days) 4 (3, 7) 4 (3, 6)  0.5819 
Censored 8 7  
Time to mediastinal drain removal (hours) 26.1 (20.6, 53.3) 22.5 (19.4, 37.8)  0.0157 
Censored 2 2  
Time to extubation (hours) 9.2 (7.8, 12.1) 8.3 (6.8, 11.7)  0.5488 
Censored 1 1  
Theatre time (minutes) 191 (172, 225) 176 (152, 203) < 0.0001 
Censored 0 0  
CPB time (minutes) 80 (70, 95) 66 (52, 85)  < 0.0001 
Censored 0 0  
Cross-clamp time (minutes) 65 (53, 76) 49 (39, 64)  < 0.0001 
Censored 0 0  
Surgery duration (minutes) 163 (139, 190) 149 (114, 167)  < 0.0001 
Censored 3 4  
*Log-rank test. Seven surgery durations were not recorded and censored at 1 minute.  418 
  419 
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Table 3. Costs, QALYs and Cost-effectiveness 420 
 Cost and QALYs  
(with imputation)  
 
FS (n = 118) MS (n = 104) 
Mean Cost 
per patient 
SD Mean Cost 
per patient 
SD 
Primary Admission 
Costs 
Theatre use £3,824 £1,243 £4,422 £2,053 
Additional surgical items £16.52 £0.0 £52.0 £0.0 
Critical care (ITU) £1,834 £3,023 £2,934 £5,030 
Cardiac ward £2,744 £1,664 £2,676 £1,500 
Physio- and Occupational Therapy £77 £55 £78 £68 
Rehabilitation £384 £1,878 £263 £1,621 
Acute hospital £347 £1,919 £298 £1,971 
Sub-total cost £9,226 £6,511 £10,724 £8,850 
Post primary 
admission costs to 
12 months 
Hospital Re-admission £418 £1,475 £575 £1,863 
Follow up tests £224 £258 £282 £279 
Follow up healthcare visits £373 £359 £311 £263 
           Sub-total cost £1,015 £1,778 £1,168 £2,079 
 
Drugs 
 
£379 
 
£548 
 
£441 
 
£977 
Total cost over 12 months £10,620 £7,624 £12,333 £9,864 
Incremental cost- 
effectiveness*  
(probabilistic 
analysis with 
baseline 
Incremental cost at 12 months (MS-FS) £2,154.0 (SE £36) 
Incremental EQ-5D-3L QALYs (MS-FS) -0.0122 (SE 0.0008) 
ICER MS dominated by FS 
NMB (at WTP £20,000/QALY) -£2,397 
NMB (at WTP £30,000/QALY) -£2,519 
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adjustment) 
SD: standard deviation, SE: standard error, WTP: willingness to pay, NMB: net monetary benefit, ICER: incremental 
cost-effectiveness ratio.  * Incremental costs and effects estimated using SUR, adjusting for baseline differences. 
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6 month follow up n=101 
Withdrawn/Lost to follow-up n=7 
Missed n=6 
Died n=4 
6 week follow up n=105 
Withdrawn/Lost to follow-up n=3 
Missed n=6 
Died n=4 
 
Allocated to MS, n =118  
Received allocated intervention n=104 
Conversion to full median sternotomy n=6 
 Aorta inter positional graft required n=1 
 Intraoperative injury requiring CABG n=2 
 Aortic root replacement required n=1 
 Calcified aorta n=1 
 Bleeding from aortic root n=1 
Did not receive allocated intervention n=8 
  FS indicated as ARR required n=1 
Ineligible for trial, underwent FS n = 1  
 Unable to have TOE post randomisation n=4 
Correct equipment unavailable n=2 
 
6 week follow up n=96 
Withdrawn/Lost to follow-up n=3 
Missed n=4 
Died n=1 
 
Assessed for eligibility, n=1024 
Declined trial participation n=72 
Training cases n=42 
                              Closed to recruitment n=11 
Screen Fail =677 
 
12 month follow up n=98 
Withdrawn/Lost to follow-up n=8 
Missed n=5 
Died n=7 
 
12 month follow up n=82 
Withdrawn/Lost to follow-up n=6  
Missed n=12 
Died n=4 
 
6 month follow up n=93 
Withdrawn/Lost to follow-up n=5 
Missed n=4 
Died n=2 
Allocated to FS, n=104 
Received allocated intervention n=103 
Withdrawn pre-operatively n = 1 
RANDOMISATION 
n= 222 
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Appendix A: Statistical Analysis 
 
 
Table A1. All patients who underwent a redo sternotomy, or crossed over from mini- to full sternotomy, or 
were randomised but found to be ineligible 
 
 Allocated 
treatment Description 
Per-protocol 
population 
Safety 
population 
     
Redos  FS Return to theatre for ventricular septal defect closure and redo-AVR. As FS As FS 
 FS Return to theatre for tamponade and cardiac arrest. Redo sternotomy for 
tamponade. 
As FS As FS 
 MS Return to theatre for tamponade MA bleed. Conversion to FS. As MS As MS 
 MS Return to theatre for bleeding. Redo FS. As MS As MS 
 MS Return to theatre for tamponade. Evacuation of clot/pericardial effusion. 
Conversion to FS. 
As MS As MS 
 MS Return to theatre for cardiac arrest and tamponade. Emergency re-
sternotomy (FS), tamponade and aortotomy repair. 
As MS As MS 
 MS Return to theatre for pericardial collection and early tamponade. PEA arrest. 
Re-exploration on bypass. Completion FS. 
As MS As MS 
 MS Second return to theatre. Attempted weaning of ECMO and placement of 
RVAD. Removal of blood clot. Redo sternotomy. 
As MS As MS 
     
Crossovers  MS Aortic root replacement required, FS indicated. Excluded As FS 
 MS FS indicated as unable to perform TOE. Excluded As FS 
 MS Aorta interposition graft required. Excluded As MS 
 MS FS indicated as unable to have TOE. Excluded As FS 
 MS Needed CABG due to intraoperative injury. Excluded As MS 
 MS Needed CABG due to intraoperative injury. Excluded As MS 
 MS FS indicated as unable to perform TOE. Excluded As FS 
 MS Required aortic root replacement, conversion to FS. Excluded As MS 
 MS Patient randomised too early - unable to insert TOE probe. Excluded As FS 
 MS Did not have correct equipment in theatre. Excluded As FS 
 MS Mini-sternotomy equipment not available. Excluded As FS 
 MS Bleeding. Excluded As MS 
 MS Patient had calcified aorta. Nowhere to cannulate safely.  Excluded As MS 
     
Ineligible FS Withdrawn from trial by surgeon pre-operatively (but post-randomisation) as 
required AVR and myectomy. 
Excluded Excluded 
 FS Poor quality baseline echocardiogram, with no assessment of LV function. Excluded As FS 
 MS Surgeon had not checked echo report until after randomisation. Underwent 
FS. 
Excluded As FS 
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Table A2. Additional summaries of in-hospital endpoints  
 Mini-sternotomy  
(n = 118) 
Full sternotomy  
(n = 104) 
   
Time to discharge (days)   
Mean (standard error) 9.5 (0.6) 8.6 (0.5) 
Median (95% confidence interval) 7 (6, 8) 7 (6, 8) 
   
Time until fit for discharge (days)   
Mean (standard error) 8.5 (0.5)* 7.5 (0.3)* 
Median (95% confidence interval) 6 (5, 7) 6 (6, 7) 
   
Time to first mobilisation (days)   
Mean (standard error) 5.7 (0.5)* 4.9 (0.3)* 
Median (95% confidence interval) 4 (3, 4) 4 (-, -) 
   
Time to mediastinal drain removal (hours)   
Mean (standard error) 48.1 (4.8)* 30.0 (1.7) 
Median (95% confidence interval) 26.1 (22.8, 42.6) 22.5 (22.0, 22.9) 
   
Time to first extubation (hours)   
Mean (standard error) 13.1 (1.7)* 10.5 (0.7) 
Median (95% confidence interval) 9.2 (8.7, 9.9) 8.3 (8.0, 9.2) 
   
 
Table A2 shows Kaplan-Meier estimates of in-hospital endpoints. Censoring of longest time to event for some 
endpoints led to underestimation of means and standard errors (highlighted with asterisks). A confidence interval 
for median time to mobilisation could not be estimated.   
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Table A3. Additional summaries of operative endpoints 
 
 Mini-sternotomy  
(n = 118) 
Full sternotomy  
(n = 104) 
   
Theatre time (minutes)   
Mean (standard error) 201.2 (3.9) 181.0 (4.6) 
Median (95% confidence interval) 191 (187, 205) 176 (170, 180) 
   
CPB time (minutes)   
Mean (standard error) 82.0 (1.9) 69.5 (2.3) 
Median (95% confidence interval) 80 (77, 86) 66 (59, 74) 
   
Cross clamp time (minutes)   
Mean (standard error) 65.5 (1.5) 52.4 (1.6) 
Median (95% confidence interval) 65 (61, 69) 49 (45, 53) 
   
Surgery duration (minutes)   
Mean (standard error) 165.5 (3.4) 145.7 (4.3) 
Median (95% confidence interval) 163(155, 172) 148.5 (134, 153) 
   
Total theatre time, including repeats/readmissions (minutes)   
Mean (standard error) 221.1 (9.5) 191.2 (6.1) 
Median (95% confidence interval) 196 (189, 210) 178.5 (171, 188) 
   
Total CPB time, including repeats/readmissions (minutes)   
Mean (standard error) 85.1 (2.6) 71.1 (2.8) 
Median (95% confidence interval) 82 (77, 87) 66 (59, 74) 
   
Total cross clamp time, including repeats/readmissions (minutes)   
Mean (standard error) 66.1 (1.6) 53.5 (2.0) 
Median (95% confidence interval) 66 (61, 70) 49 (45, 53) 
   
Volume of blood lost in the first 12 postoperative hours (ml)   
Mean (SD) 310.4 (342.5) 323.2 (267.8) 
Median (quartiles) 225 (150, 325) 250 (175, 375) 
   
Transfusion of packed red cells in the first 48 postoperative hours (ml)   
Number of transfused patients (%)  50 (42%) 51 (49%) 
Mean (SD) in transfused patients 625.3 (513.2) 442.4 (265.3) 
Median (quartiles) in transfused patients  500 (300, 644)  303 (284, 569) 
   
Transfusion of clotting products in the first 48 postoperative hours (ml)   
Number of transfused patients (%) 11 (9%) 4 (4%) 
Mean (SD) in transfused patients  920.5 (1438.4) 753.0 (672.5) 
Median (quartiles) in transfused patients  332 (183, 1050) 625 (209, 1297) 
   
 
All estimates for time-to-event endpoints in Table A3 are Kaplan-Meier estimates. Time data were complete, 
except for seven surgery durations (3 MS, 4 FS) that were not recorded and were therefore censored at 1 minute. 
Blood data were only missing for one patient (FS group, withdrawn before surgery). Blood transfusion and 
clotting products data for seven patients at the Freeman hospital were recorded in units and converted to ml (1 
unit PRC = 300ml, 1 unit platelets = 245ml, 1 unit FFP = 280ml). Transfusion data were explored using logistic 
regression models, including fixed effects for treatment, valve and sex, and a random surgeon effect. These 
analyses did not show a statistically significant difference between MS and FS patients in either need for blood 
transfusion (MS/FS odds ratio 0.797, confidence interval 0.453 to 1.402, p-value 0.4310) or the need for 
transfusion of clotting products (MS/FS odds ratio 2.616, confidence interval 0.801 to 8.541, p-value 0.1112). 
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Table A4. Results from Cox models and log-rank tests for primary and secondary endpoints 
 
 
MS/FS hazard ratio  
(95% confidence interval) 
p-value for null 
hypothesis HR = 1 
Log-rank 
test statistic 
p-value from 
log-rank test 
     
Primary analyses     
Time to discharge 0.874 (0.668,1.143) 0.3246 0.157 0.6924 
Time until fit 0.907 (0.688,1.197) 0.4914 0.340 0.5597 
     
Per protocol analyses of primary endpoints     
Time to discharge 0.868 (0.656,1.147) 0.3194 0.200 0.6544 
Time until fit 0.915 (0.688,1.218) 0.5443 0.217 0.6415 
     
Sensitivity analyses: 
age included as an effect in the Cox models 
    
Time to discharge 0.866 (0.661,1.135) 0.2985 0.157 0.6924 
Time until fit 0.902 (0.683,1.192) 0.4685 0.340 0.5597 
     
Sensitivity analyses: 
EuroSCORE included as an effect in the Cox models 
    
Time to discharge 0.885 (0.676,1.159) 0.3753 0.157 0.6924 
Time until fit 0.936 (0.709,1.236) 0.6400 0.340 0.5597 
     
Sensitivity analyses: 
censoring times taken as event times: 
    
Time to discharge 0.884 (0.677,1.153) 0.3625 0.189 0.6639 
Time until fit 0.888 (0.680,1.160) 0.3844 0.765 0.3819 
     
Sensitivity analysis: 
patients assumed to be fit at discharge 
    
Time until fit 0.879 (0.671, 1.151) 0.3480 0.703 0.4018 
     
Secondary endpoint analyses     
Time until first mobilisation  0.899 (0.680,1.187) 0.4518 0.303 0.5819 
Time until drain removal 0.587 (0.442,0.778) 0.0002 5.838 0.0157 
Time until first extubation 0.856 (0.655,1.120) 0.2582 0.359 0.5488 
     
Exploratory analyses     
Surgery duration 0.660 (0.500,0.872) 0.0035 17.892 < 0.0001 
CPB time 0.592 (0.448,0.782) 0.0002 24.871 < 0.0001 
Cross clamp time 0.451 (0.340,0.597) < 0.0001 42.539 < 0.0001 
Theatre time 0.665 (0.503,0.879) 0.0042 16.806 < 0.0001 
Total CPB time including repeats/readmissions 0.547 (0.414,0.723) < 0.0001 20.176 < 0.0001 
Total cross clamp time including repeats/readmissions 0.458 (0.346,0.608) < 0.0001 34.352 < 0.0001 
Total theatre time including repeats/readmissions 0.698 (0.531,0.918) 0.0102 5.657 0.0174 
Time to death by any cause 1.871 (0.723, 4.844) 0.1966 0.7309 0.3926 
     
 
Table A4 shows the results of all analyses performed for the primary and secondary time-to-event endpoints, 
including unplanned, exploratory analyses of secondary endpoints. All secondary endpoint analyses, sensitivity 
analyses and exploratory analyses were performed using the intent to treat population. All log-rank tests were 
stratified by valve, sex and surgeon. All Cox models included valve, sex and treatment as fixed effects, and 
surgeon as a random effect. Exploratory analysis of time to all-cause death included age as a fixed effect in the 
Cox model. Mean imputation was used for missing EuroSCORE data at baseline (1 MS).     
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Table A5.  Summaries of pain at rest scores in the first ten days following surgery 
 
  Mini-sternotomy (n = 118) Full sternotomy (n = 104) 
    
Day 1 Mean (SD) 3.5 (2.5) 3.7 (2.4) 
 n  100 (85%) 82 (80%) 
    
Day 2 Mean (SD) 3 (2.3) 3.1 (2.5) 
 n  89 (75%) 81 (79%) 
    
Day 3 Mean (SD) 2.7 (2.3) 2.4 (2.3) 
 n  91 (77%) 83 (81%) 
    
Day 4 Mean (SD) 2.4 (2.1) 2.4 (2.4) 
 n  94 (80%) 84 (82%) 
    
Day 5 Mean (SD) 2 (1.9) 2.1 (2) 
 n 90 (79%) 80 (79%) 
    
Day 6 Mean (SD) 1.8 (1.7) 2.1 (2) 
 n  69 (77%) 61 (76%) 
    
Day 7 Mean (SD) 1.5 (1.8) 1.8 (2) 
 n  46 (69%) 42 (78%) 
    
Day 8 Mean (SD) 1.2 (1.4) 1.7 (1.6) 
 n  40 (77%) 35 (76%) 
    
Day 9 Mean (SD) 1 (1.8) 0.8 (1.5) 
 n  25 (57%) 18 (47%) 
    
Day 10 Mean (SD) 0.7 (1) 1.3 (2) 
 n  18 (47%) 12 (43%) 
    
 
Table A5 shows the number of pain scores taken for each of the 10 days following surgery. The denominator 
used for each percentage is the number of patients known to be alive and in hospital on the given day.  
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Table A6.  Summaries of EQ-5D utility scores up to the 12 month follow-up 
 
  Mini-sternotomy (n = 118) Full sternotomy (n = 104) 
    
Baseline Mean (SD) 0.77 (0.19) 0.70 (0.24) 
 n  105 (89%) 95 (91%) 
    
Day 4 Mean (SD) 0.47 (0.29) 0.39 (0.28) 
 n  92 (78%) 89 (86%) 
    
Discharge Mean (SD) 0.60 (0.24) 0.58 (0.24) 
 n  103 (87%) 88 (85%) 
    
Six weeks Mean (SD) 0.74 (0.23) 0.71 (0.21) 
 n  106 (90%) 88 (85%) 
    
Six months Mean (SD) 0.83 (0.25) 0.83 (0.23) 
 n 105 (89%) 95 (91%) 
    
Twelve months Mean (SD) 0.83 (0.29) 0.78 (0.28) 
 n 103 (87%) 84 (81%) 
    
 
For patients who died, EQ-5D scores were taken to be zero following death. Percentages presented in Table A6 
were calculated as the number of scores recorded (including the zeros) divided by the number of patients 
randomised to the group. The difference in mean baseline score was potentially due to the imbalance in gender 
(the FS group has a greater proportion of females, who reported lower quality of life on average).  
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Table A7.  Summaries of SF-36 domain scores up to the 12 month follow up 
 
   Mini-sternotomy (n = 118) Full sternotomy (n = 104) 
 
Bodily pain Baseline Mean (SD) 70 (25) 64 (28) 
  n 104 (88%) 96 (92%) 
 Six weeks Mean (SD) 61 (24) 60 (23) 
  n 105 (89%) 90 (87%) 
 Six months Mean (SD) 79 (27) 74 (28) 
  n 104 (88%) 94 (90%) 
 Twelve months Mean (SD) 76 (31) 72 (32) 
  n 99 (84%) 86 (83%) 
 
General health Baseline Mean (SD) 62 (20) 58 (22) 
  n 104 (88%) 94 (90%) 
 Six weeks Mean (SD) 70 (20) 66 (20) 
  n 104 (88%) 91 (88%) 
 Six months Mean (SD) 71 (24) 66 (24) 
  n 103 (87%) 94 (90%) 
 Twelve months Mean (SD) 68 (26) 62 (26) 
  n 100 (85%) 86 (83%) 
 
Mental health Baseline Mean (SD) 74 (18) 67 (21) 
  n 104 (88%) 95 (91%) 
 Six weeks Mean (SD) 72 (22) 73 (19) 
  n 104 (88%) 91 (88%) 
 Six months Mean (SD) 80 (21) 74 (22) 
  n 103 (87%) 94 (90%) 
 Twelve months Mean (SD) 76 (26) 73 (23) 
  n 100 (85%) 86 (83%) 
 
Physical functioning Baseline Mean (SD) 54 (26) 47 (28) 
  n 105 (89%) 96 (92%) 
 Six weeks Mean (SD) 63 (22) 56 (23) 
  n 105 (89%) 91 (88%) 
 Six months Mean (SD) 78 (27) 70 (28) 
  n 104 (88%) 94 (90%) 
 Twelve months Mean (SD) 74 (30) 67 (31) 
  n 100 (85%) 86 (83%) 
 
Role emotional Baseline Mean (SD) 67 (40) 55 (46) 
  n 104 (88%) 94 (90%) 
 Six weeks Mean (SD) 60 (44) 63 (43) 
  n 104 (88%) 90 (87%) 
 Six months Mean (SD) 81 (35) 72 (42) 
  n 104 (88%) 94 (90%) 
 Twelve months Mean (SD) 76 (39) 71 (42) 
  n 98 (83%) 85 (82%) 
     
Role physical Baseline Mean (SD) 33 (41) 23 (38) 
  n 103 (87%) 96 (92%) 
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 Six weeks Mean (SD) 19 (32) 20 (33) 
  n 103 (87%) 90 (87%) 
 Six months Mean (SD) 65 (42) 59 (44) 
  n 103 (87%) 94 (90%) 
 Twelve months Mean (SD) 64 (44) 52 (46) 
  n 98 (83%) 85 (82%) 
 
Social functioning Baseline Mean (SD) 66 (30) 61 (29) 
  n 104 (88%) 94 (90%) 
 Six weeks Mean (SD) 66 (29) 68 (27) 
  n 104 (88%) 91 (88%) 
 Six months Mean (SD) 85 (26) 78 (28) 
  n 102 (86%) 93 (89%) 
 Twelve months Mean (SD) 81 (30) 78 (30) 
  n 98 (83%) 85 (82%) 
 
Vitality Baseline Mean (SD) 46 (25) 40 (23) 
  n 104 (88%) 95 (91%) 
 Six weeks Mean (SD) 50 (22) 48 (22) 
  n 104 (88%) 90 (87%) 
 Six months Mean (SD) 64 (23) 57 (23) 
  n 103 (87%) 94 (90%) 
 Twelve months Mean (SD) 60 (26) 54 (26) 
  n 100 (85%) 86 (83%) 
     
 
An in-house implementation of the standard scoring algorithm for the developmental version of SF-36 was used. 
For patients who died, SF-36 scores were taken to be zero following death. Percentages presented in Table A7 
were calculated as the number of scores recorded (including the zeros) divided by the number of patients 
randomised to the group. The differences in mean baseline scores were potentially due to the imbalance in 
gender (the FS group has a greater proportion of females, who reported lower quality of life on average).  
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
 
 
 
10 
 
Table A8. Estimated treatment effects (MS - FS) and treatment-time interactions for SF-36 domain scores 
up to 12 months, EQ-5D utility scores up to 12 months and pain scores up to discharge 
 
 Effect (MS ± FS) 95% confidence interval p-value 
    
Pain at rest (n = 219)    
Treatment effect 0.0 (-0.7, 0.6) 0.9766 
Treatment-time (days) interaction  0.0 (-0.1, 0.1) 0.8190 
    
EQ-5D utility scores (n = 197)    
Treatment effect 0.02 (-0.03, 0.07) 0.5148 
Treatment-time (months) interaction 0.00 (-0.01, 0.01) 0.9731 
    
SF-36 physical functioning (n = 192)    
Treatment effect 1.2 (-6.2, 8.7) 0.7414 
Treatment-time (months) interaction 0.3 (-0.2, 0.9) 0.2387 
    
SF-36 role physical (n = 190)    
Treatment effect -8.3 (-21.1, 4.5) 0.2025 
Treatment-time (months) interaction 1.7 (0.3, 3.1) 0.0169 
    
SF-36  bodily pain (n = 191)    
Treatment effect -0.7 (-9.1, 7.8) 0.8792 
Treatment-time (months) interaction 0.3 (-0.5, 1.1) 0.4331 
    
SF-36  general health (n = 189)    
Treatment effect -1.0 (-7.5, 5.5) 0.7710 
Treatment-time (months) interaction 0.3 (-0.2, 0.8) 0.2224 
    
SF-36  vitality (n = 190)    
Treatment effect -2.1 (-8.8, 4.5) 0.5273 
Treatment-time (months) interaction 0.6 (0.1, 1.2) 0.0293 
    
SF-36  social functioning (n = 189)    
Treatment effect -5.5 (-14.1, 3.1) 0.2093 
Treatment-time (months) interaction 1.0 (0.2, 1.7) 0.0183 
    
SF-36  role emotional (n = 189)    
Treatment effect -6.2 (-18.6, 6.2) 0.3255 
Treatment-time (months) interaction 1.1 (-0.1, 2.3) 0.0699 
    
SF-36 mental health (n = 190)    
Treatment effect -3.2 (-9.7, 3.4) 0.3431 
Treatment-time (months) interaction 0.5 (-0.0, 1.0) 0.0702 
    
 
Table A8 shows results of complete case analyses of questionnaire data, under a missing completely at random 
assumption, including only patients with at least one analysable follow-up questionnaire. For each analysis, the 
n in parentheses is number of patients used to fit the model. For pain and SF-36 scores, some random effects 
were estimated to have a variance of 0 and were excluded from the models (surgeon effect for pain, and both the 
surgeon effect and random slope for SF-36). The slope (time coefficient) was estimated to be negative for pain 
and positive for all EQ-5D and SF-36 scores. This suggests improvement over time in each score. Evidence of 
greater rate of improvement over time for MS patients (statistically significant, positive interaction term) was 
seen for three SF-36 domains (role physical, vitality, and social functioning), but no others. 
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Table A9. Estimated treatment effects (MS-FS) and treatment-time interactions for SF-36 domain scores 
up to 12 months, EQ-5D utility scores up to 12 months and pain scores up to discharge, after multiple 
imputation of missing scores 
 
 Effect (MS ± FS) 95% confidence interval p-value 
    
Pain at rest    
Treatment effect 0.0 (-0.7, 0.6) 0.9059 
Treatment-time (days) interaction 0.0 (-0.1, 0.1) 0.9685 
    
EQ-5D utility scores    
Treatment effect 0.01 (-0.04, 0.06) 0.8203 
Treatment-time (months) interaction 0.00 (-0.01, 0.01) 0.9094 
    
SF-36 physical functioning    
Treatment effect 2.0 (-4.9, 8.9) 0.5744 
Treatment-time (months) interaction 0.2 (-0.3, 0.8) 0.3996 
    
SF-36 role physical     
Treatment effect -6.6 (-18.7, 5.4) 0.2808 
Treatment-time (months) interaction 1.5 (0.1, 2.8) 0.0310 
    
SF-36  bodily pain     
Treatment effect -0.1 (-9.0, 7. 7) 0.9748 
Treatment-time (months) interaction 0.3 (-0.4, 1.1) 0.4091 
    
SF-36  general health     
Treatment effect 1.1 (-5.0, 7.3) 0.7175 
Treatment-time (months) interaction 0.2 (-0.3, 0.7) 0.3373 
    
SF-36  vitality    
Treatment effect -0.5 (-6.9, 5.9) 0.8798 
Treatment-time (months) interaction 0.4 (-0.2, 1.0) 0.1733 
    
SF-36  social functioning    
Treatment effect -4.4 (-12.4, 3.5) 0.2756 
Treatment-time (months) interaction 0.7 (0.0, 1.5) 0.0589 
    
SF-36  role emotional    
Treatment effect -4.6 (-16.4, 7.2) 0.4415 
Treatment-time (months) interaction 0.8 (-0.4, 2.0) 0.1790 
    
SF-36 mental health     
Treatment effect -2.5 (-8.6, 3.5) 0.4113 
Treatment-time (months) interaction 0.4 (-0.1, 0.9) 0.1195 
    
 
Table A9 shows the results from analysing the questionnaire data using multiple imputation to handle missing 
observations, under a missing at random assumption. For each analysis, missing data were imputed from models 
that included all other variables used in the analysis, along with CCS grading and NYHA grading as auxiliary 
variables. The method used was multiple imputation by chained equations with predictive mean matching. 
Estimates from 100 imputed data sets ZHUHFRPELQHGXVLQJ5XELQ¶VUXOHVPain was only imputed for patients 
known to be alive and in hospital, not for patients who had died or had already been discharged. Evidence of 
greater rate of improvement over time for MS patients (statistically significant, positive interaction term) was 
seen only for one SF-36 domain.  
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Figure A1. Forest plots of mean pain scores for the first 10 days following surgery, with 95% confidence 
intervals 
 
In Figure A1, means on each day were adjusted for sex and valve type, and were estimated from the complete 
case analysis. 
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Figure A2. Forest plot of mean EQ-5D scores at each follow-up time, with 95% confidence intervals 
 
In Figure A2, means at each follow-up time were adjusted for baseline EQ-5D, sex and valve type, and were 
estimated from the complete case analysis.  
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Figure A3. Forest plot of mean SF36 domain scores at each follow-up time, with 95% confidence intervals 
 
In Figure A3, means at each follow-up time were adjusted for baseline domain score, sex and valve type, and 
were estimated from the complete case analysis. A score of 100 represents no disability, and a score of 0 
represents maximum disability. 
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 Table A10. Summaries heart function (LVEF) and respiratory function (FEV1) 
 
 Mini-sternotomy (n = 118) Full sternotomy (n = 104) 
   
FEV1 (litres):   
   
Baseline visit   
Mean (SD) 2.3 (0.7) 2.3 (0.8) 
Median (quartiles) 2.2 (1.8, 2.7) 2.2 (1.7, 2.6) 
n 115 101 
   
Discharge    
Mean (SD) 1.6 (0.6) 1.6 (0.6) 
Median (quartiles) 1.5 (1.2, 1.8) 1.5 (1.2, 1.9) 
n 82 69 
   
6 week visit   
Mean (SD) 2.1 (0.8) 2.1 (0.7) 
Median (quartiles) 2 (1.5, 2.5) 1.9 (1.6, 2.5) 
n 92 84 
   
6 month visit   
Mean (SD) 2.2 (0.7) 2.1 (0.7) 
Median (quartiles) 2.1 (1.7, 2.6) 1.9 (1.4, 2.4) 
n 91 82 
   
   
LVEF (%):   
   
Baseline visit   
Mean (SD) 61.9 (9.1) 62.4 (8.6) 
Median (quartiles) 62.5 (57.5, 67.5) 63 (57.5, 67.0) 
n 117 101 
   
Discharge   
Mean (SD) 59.9 (9.7) 59 (10.2) 
Median (quartiles) 62 (55.0, 65.0) 58 (55.0, 64.5) 
n 106 96 
   
6 month visit   
Mean (SD) 61.2 (8.1) 61.8 (9.7) 
Median (quartiles) 61 (56.0, 67.5) 62.5 (56.3, 68.0) 
n 97 88 
   
 
FEV1 is forced expiratory volume in one second, measured by hand-held spirometry. LVEF is left ventricular 
ejection fraction, measured by echocardiography. No analyses were planned for these endpoints. 
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Table A11. Frequency of non-fatal SAEs (number of patients) within one year of surgery, by treatment 
received  
  Mini-sternotomy (n = 110) Full sternotomy (n = 111) Total (n = 221) 
    
Cardiac (including atrial fibrillation, conduction 
problems, need for permanent pacemaker) 
43 (29) 
 
27 (21) 
 
70 (50) 
 
Respiratory 20 (14) 9 (8) 29 (22) 
Injury/procedural 19 (11) 7 (6) 26 (17) 
Non-cardiorespiratory infection (including wound)  7 (7) 12 (9) 19 (16) 
Urinary 11 (10) 8 (6) 19 (16) 
Surgical and medical procedures 9 (6) 7 (7) 16 (13) 
Nervous system 8 (8) 7 (7) 15 (15) 
Cardiorespiratory infection (including endocarditis, 
device-related infections, chest infection) 
9 (9) 6 (5) 15 (14) 
Vascular 9 (9) 1 (1) 10 (10) 
Psychiatric 5 (5) 5 (5) 10 (10) 
Gastro-intestinal ± diarrhoea 7 (6) 3 (3) 10 (9) 
Gastro-intestinal ± other 7 (7) 1 (1) 8 (8) 
General disorders 4 (4) 3 (2) 7 (6) 
Metabolic 2 (2) 3 (2) 5 (4) 
Blood/lymph 4 (3) 1 (1) 5 (4) 
Neoplasms 1 (1) 1 (1) 2 (2) 
Hepatitis/cholecystitis 1 (1) 1 (1) 2 (2) 
Musculoskeletal 2 (2) 0 (0) 2 (2) 
Skin/tissue 0 (0) 1 (1) 1 (1) 
Eye 0 (0) 1 (1) 1 (1) 
Immune 0 (0) 1 (1) 1 (1) 
    
Total 168 (56) 105 (46) 273 (102) 
    
 
Among the nervous system SAEs recorded in Table A11, strokes were suffered by 3 FS recipients and 2 MS 
recipients. No patient suffered more than one stroke.
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Table A12. Frequencies of non-death SAEs (and number of patients experiencing them), within a year of 
surgery, at each level of severity, expectedness and relatedness, by treatment received 
  
 Mini-sternotomy (n = 110) Full sternotomy (n = 111) Total (n = 221) 
    
Cardiorespiratory:    
    
Severity    
Severe 26 (14) 14 (11) 40 (25) 
Moderate 34 (24) 24 (18) 58 (42) 
Mild 12 (11) 4 (4) 16 (15) 
    
Expectedness    
Expected 69 (38) 42 (30) 111 (68) 
Unexpected 3 (2) 0 (0) 3 (2) 
    
Relatedness    
Probably related 4 (4) 2 (2) 6 (6) 
Possibly related 50 (30) 32 (25) 82 (55) 
Unrelated 18 (13) 8 (6) 26 (19) 
    
Total 72 (38) 42 (30) 114 (68) 
    
    
Non-cardiorespiratory:    
    
Severity    
Severe 40 (21) 24 (15) 64 (36) 
Moderate 43 (29) 31 (21) 74 (50) 
Mild 13 (11) 8 (5) 21 (16) 
    
Expectedness    
Expected 68 (34) 45 (27) 113 (61) 
Unexpected 28 (15) 18 (15) 46 (30) 
    
Relatedness    
Probably related 9 (5) 5 (5) 14 (10) 
Possibly related 37 (22) 30 (20) 67 (42) 
Unrelated 50 (27) 28 (20) 78 (47) 
    
Total 96 (41) 63 (34) 159 (75) 
    
 
The only unexpected events in the MS group were a bilateral pleural effusion in one patient, and bronchial 
aspiration and peri-arrest event in another. Both patients completely recovered. Exploratory analysis in the 
safety population, using logistic regression (with fixed treatment, valve and sex effects, and a random surgeon 
effect), did not show a statistically significant difference between MS and FS recipients in the odds of suffering 
a non-death SAE within the first year (MS/FS odds ratio 1.559, confidence interval 0.895 to 2.715 and p-value 
0.1161). An exploratory Poisson regression (with a fixed effect for treatment and a random patient effect) did 
show a greater rate of such SAEs for MS recipients (MS/FS rate ratio 1.615, confidence interval 1.070 to 2.437, 
p-value 0.0225). There were 7 pericardial tamponades in total (4 for FS recipients, 3 for MS recipients, only one 
per patient), but logistic regression (without the random surgeon effect) did not produce a statistically significant 
result (MS/FS odds ratio 0.680, confidence interval 0.146 to 3.178, p-value 0.6229). 
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Table A13. Frequency of paraprosthetic regurgitation, by treatment received 
 
 Mini-sternotomy (n = 110) Full sternotomy (n = 111) Total (n = 221) 
    
Discharge    
No regurgitation 84 85 169 
Mild regurgitation 19 16 35 
Moderate regurgitation 0 0 0 
Severe regurgitation 0 0 0 
n 101 103 204 
    
6 month visit    
No regurgitation 77 82 159 
Mild regurgitation 18 10 28 
Moderate regurgitation 0 0 0 
Severe regurgitation 0 0 0 
n 95 92 187 
    
 
Paraposthetic regurgitation was explored using logistic regressions at each time point. These were performed as 
complete case analyses, in the safety population. Logistic regression models included fixed treatment, valve and 
sex effects, and a random surgeon effect. They did not show a statistically significant difference between MS 
recipients and FS recipients in the odds of regurgitation, either at discharge (MS/FS odds ratio 1.163, confidence 
interval 0.553 to 2.445, p-value 0.6883) or at 6 months (MS/FS odds ratio 1.880, confidence interval 0.798 to 
4.430, p-value 0.1480). 
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Table A14. All wound infections within the first year after surgery, by treatment received 
 
Treatment 
received Relationship Description 
   
FS Possibly related Superficial sternal wound infection. 
FS Possibly related Sternal wound infection. Returned to theatre for debridement and 2x wires removed. 
FS Possibly related Sternal wound infection. 
FS Possibly related Sternal wound breakdown. Debridement and excision of sinuses.  PICC line inserted for 6 weeks 
IV antibiotics. 
FS Possibly related Drain site wound infection. 
FS Possibly related Wound infection - small area at lower end of sternum. 
FS Possibly related Small sternal wound infection. 
FS Probably related Sternal wound infection. 
FS Probably related Sternal wound infection. 
FS Possibly related Sternal wound infection. 
FS Probably related Sternal wound infection. 
FS Possibly related Sternal wound infection. Antibiotics commenced. 
FS Possibly related Sternal wound infection - requiring hospital admission. Treated with antibiotics. 
FS Possibly related Wound Infection. Commenced on antibiotics and daily dressings. 
   
MS Possibly related Readmission, wound infection, iv/oral flucloxacillin. 
MS Possibly related MRSA sternal wound infection. 
MS Probably related Sternal wound infection. Admitted to NGTH with fever, chest pain, SOB and discharging sternal 
wound. Commenced IV flucloxacillin. Swab taken, VAC dressing applied. 
MS Possibly related Wound infection at base of sternotomy. Wound swab taken, grown K.pneumoniae. Commenced 
antibiotics - amoxycillin. 
   
 
In total, 4 MS recipients and 13 FS recipients suffered wound infections within a year of surgery (one FS 
recipient suffered two infections). No patients who received a mechanical valve suffered a wound infection. 
Odds of wound infection were explored via logistic regression (complete case analysis in the safety population, 
with fixed treatment and sex effects, and with a random surgeon effect). The odds of suffering at least one 
wound infection were estimated to be lower for MS recipients than for FS recipients (MS/FS odds ratio 0.312, 
confidence interval 0.097 to 1.005, p-value 0.0511). Only two infections were categorised as deep (1 MS, 1FS).  
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Table A15. All deaths 
 
 Treatment 
received 
Treatment 
allocated 
Cause Relationship to 
treatment 
Days from 
surgery to death 
      
Cardiorespiratory  FS FS Endocarditis and sepsis. Possibly related 124 
 FS FS Lung infection. Unrelated 1050 
 FS FS Respiratory failure, pneumonia, chronic lymphocytic leukaemia. Unrelated 1057 
      
 MS MS Cardiac arrest and pericardial tamponade 2 days after surgery. 
Heart failure and left anterior pneumothorax 3 days after surgery.  
Possibly related 3 
 MS MS Type 2 respiratory failure and shock, multi-organ failure. Possibly related 24 
 MS MS Post-op arrest on HDU on day of surgery. Heart failure 26 days 
after surgery. 
Possibly related 26 
 MS MS Lower respiratory tract infection. Type 2 respiratory failure. 
NSTEMI during hospital admission. 
Unrelated 75 
 MS MS Endocarditis, infected valve. Refused all treatment including 
antibiotics. Palliation only.  
Possibly related 241 
 MS MS Exacerbation of COPD. Unrelated 307 
 MS MS Ischaemic heart disease. Unrelated 502 
 MS MS Myocardial infarction. Unrelated 933 
      
Non-cardiorespiratory FS FS Sepsis. Unrelated 66 
 FS FS Metastatic prostate cancer. Unrelated 256 
 FS FS B cell lymphoma. Unrelated 308 
 FS FS Embolus of left common femoral artery, advanced colorectal 
cancer, AS, CHF. 
Unrelated 958 
      
 MS MS Metastatic bladder cancer. Unrelated 257 
 MS MS Death due to malignant tumour of oesophagus Unrelated 445 
 MS MS Diffuse large B cell lymphoma. Unrelated 527 
 MS MS Spontaneous subdural haemorrhage. Unrelated 873 
      
 
Table A15 shows that none of the patients who died were considered to be crossovers from MS to FS. However, 
there were three deaths among patients who were allocated and received MS but who were returned to theatre 
for redo FS. These were the deaths, all categorised as cardiorespiratory in Table A15, which occurred at 3, 26 
and 933 days after surgery. 
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Figure A4. Kaplan-Meier curves for time to death by any cause 
 
 
Patients are grouped by the treatment allocated to them. Patients who had no fatal events recorded were 
censored at the last time they were known to be alive. Times of censoring are indicated by points on the curves.  
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Appendix B: Economic Evaluation 
 
 
Introduction 
 
This trial collected data on resource and health service use for each patient during their in-patient stay through to 
the end of follow-up at 1 year.  The economic analysis compared the costs and quality of life impacts of full and 
mini-sternotomy and assessed the cost-effectiveness of mini-sternotomy as an alternative to full median 
sternotomy. 
 
The methods section first presents the unit costs, resource use data and the methods used to aggregate resource 
use and utility data at a patient level.  The methods used to document and impute missing data follow.  The last 
part describes the construction of incremental cost-effectiveness ratios and representation of uncertainty. 
 
Results are presented first for raw data (with and without imputation) for costs and QALYs separately, followed 
by estimations of costs and QALYs that account for baseline differences. The final section provides results of 
probabilistic and deterministic sensitivity analyses. 
 
Methods 
 
Unit costs 
All resource use data collected formed part of the patient-specific case-report form.  Trained research nurses 
extracted data for inpatient stays from individual patient records.  Face-to-face interviews with patients, by 
research nurses, provided data for quality of life as well as health service use during follow-up. 
 
Multiplying the unit costs by each unit of resource use and summing WKHVHUHVRXUFHFRVWVDFURVVHDFKSDWLHQW¶V
12 month follow-up from date of operation enabled aggregation of total cost per patient. Table B1 provides the 
unit costs used, with source of data.  Where possible, national estimates of unit prices were used (e.g. PSSRU 
2015 [1], NHS Ref 2014-15 [2]) to increase generalisability. 
 
All resources were used once by patients (e.g. a GP visit or specific test), with the exception of two capital items 
used during surgery; the horizontal saw and defibrillator handles, both acquired for mini-sternotomy.  These 
costs were apportioned, using clinical opinion, to each patient assuming a lifespan of 20 years and that surgeons 
undertake a total of 255 mini-sternotomies over five years.  
  
Table B1.  Unit costs 
 
Item Source Consultation time/Codes Mean 
2014/15 
SD 
GP Visits PSSRU 2015. 10.8b Per patient contact lasting 17.2 
minutes 
£65.00 £13.00 
GP Home Visits PSSRU 2015. 10.8b Per patient contact lasting 11.7 
minutes  
£45.00 £9.00 
Nurse (GP Practice) Visits PSSRU 2015. 10.6 Per patient contact 15.5 minutes £14.47 £2.89 
Nurse (Specialist Community) 
Home Visits 
PSSRU 2015. 10.4 Per patient contact 15.5 minutes  £19.38 £3.88 
Physiotherapy (outpatient) NHS Ref 2014-15 Code: WF01A £16.13 £3.23 
Occupational Therapy (outpatient) NHS Ref 2014-15 Code: WF01A £16.67 £3.33 
Physiotherapy (inpatient) PSSRU 2015. 13.1 Per patient contact lasting 20 
minutes 
£12.67 £2.53 
Occupational Therapy (inpatient) PSSRU 2015. 13.2 Per patient contact lasting 20 
minutes 
£12.67 £2.53 
Physiotherapy (home) PSSRU 2015. 8.4.1 Per patient contact lasting 20 
minutes 
£27.00 £5.40 
Theatre use Papworth estimate   £20.00 £4.00 
Horizontal surgical saw Papworth estimate 
 
 
 
20 year life span and are used in 
255 surgeries in every 5 years 
 
£3,138.22  £3.1 
Paediatric internal cardioversion 
paddles 
£161.71  £0.2 
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Internal paddle handle £670.00  £0.7 
Reprocessing cost of defibrillator 
paddles for each surgery* 
Per patient £2.40 £2.40 
Single use saw blade for mini-
sternotomy 
Per patient £15.80 £15.80 
Single use saw blade for full 
sternotomy 
Per patient £48.00 £48.00 
Adult Critical Care NHS Ref 2014-15 Total/weighted average £1,274.92 £583.33 
Specialised Ward NHS Ref 2014-15 Code: SD01A £387.96 £77.59 
General Ward NHS Ref 2014-15 Code: SD03A £103.01 £20.60 
Rehabilitation PSSRU (1.3) 2015   £158.57 £31.71 
24 hour Blood Pressure 
Monitoring 
Lovibond et al. 2011, 
[3] 
  £61.47 £12.29 
Radiography (chest) Auguste et al. 2011, [4]   £3.46 £0.69 
Echo TTE NHS Ref 2014-15 Simple Echocardiogram £83.94 £16.79 
Echo TOE NHS Ref 2014-15 Complex Echocardiogram £128.49 £25.70 
Echo Stress NHS Ref 2014-15 Complex Echocardiogram £128.49 £25.70 
24 hour ECG NHS Ref 2014-15 Electrocardiogram Monitoring £140.69 £28.14 
12 hour ECG NHS Ref 2014-15 Electrocardiogram Monitoring £140.69 £28.14 
Exercise Tolerance Test NHS Ref 2014-15 Electrocardiogram Monitoring £140.69 £28.14 
MRI scan NHS Ref 2014-15 Total/weighted average £146.15 £56.64 
Full Pulmonary Function Testing  NHS Ref 2014-15 Code: DZ52Z £55.32 £11.06 
Cardiac Rehabilitation NHS Ref 2014-15 Code: VC38Z £97.84 £19.57 
Cardio Clinic NHS Ref 2014-15 Code: WF01A £123.02 £24.60 
Pacemaker NHS Ref 2014-15 Code: EY08E £76.32 £15.26 
Blood tests NHS Ref 2014-15 Code: DAPS08 £3.46 £0.69 
Arrhythmia clinic NHS Ref 2014-15 Total/weighted average £131.14 £26.23 
Wound clinic NHS Ref 2014-15 Code: N25AF/AN £54.93 £10.99 
A&E visit NHS Ref 2014-15 Total/weighted average £140.59 £141.05 
Computerised Tomography Scan  NHS Ref 2014-15 Total/weighted average £122.31 £48.86 
 
* The lead clinician confirmed that: defibrillator is not routinely used and that the cost of paddles should apply 
to 30% of patients; and the cost of external defibrillator plates should be excluded for mini-sternotomy as the 
plate is only used when it is not possible to insert the paddles. 
 
 
Patient-level aggregation of cost 
This section describes the aggregation of costs, by patient, for the inpatient stay, post-discharge follow-up to 12 
months and drug use. 
 
Hospital stay: The time in the hospital from randomisation to discharge was disaggregated into theatre time, 
critical care unit (CCU) stay and cardiac ward stay as shown in Table B2. The total length of stay comprised 
time spent in surgery (measured in minutes), CCU (measured in hours) and cardiac ward (measured in days).  
Theatre time included duration of re-operations where applicable (a few patients had up to two returns to 
theatre) and corresponding CCU stays were added to the CCU hours. The total stay in the hospital, calculated 
using theatre time, critical care and ward stay, was compared with direct calculation of duration using date of 
operation and date of discharge to validate the breakdown of patient stay. After discharge from hospital, the 
majority of patients were discharged home but some were referred on to acute hospitals or rehabilitation centres 
(short or long term) for more care, and the costs of this additional stay were included.  
 
Post-discharge: Resource use after discharge and up to twelve months post randomisation was collected at 6 
week, 6 month and 12 month follow-up visits, with resource use divided into three categories: hospital 
admissions, tests and healthcare visits. A total of 28 different healthcare resources were used and aggregated 
over the follow-up period. For example, if a patient reported 1 blood test in discharge to 6 week follow-up 
period, 2 blood tests between 6 week to 6 month period and none after that, resource use was costed as £10.38 
(3*£3.46) post discharge .  
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Table B2. Summary of resource use (without imputation) 
 
  Full Sternotomy Mini-sternotomy 
Primary Admission Costs Unit of 
measurement 
Obs Mean 
resource 
use/patient 
SD Obs Mean resource 
use/patient 
SD 
Theatre Minutes 104 191.19 62.15 118 221.11 102.65 
Critical care (ITU) Hours 103 34.67 57.17 118 55.24 94.69 
Cardiac ward  Days 103 7.09 4.31 118 6.90 3.87 
Rehabilitation*  Days 103 2.45 11.90 117 1.68 10.27 
Acute hospital* Days 103 0.90 4.97 117 0.74 5.09 
Physiotherapy (inpatient) Days 103 5.90 4.21 117 5.90 5.16 
Occupational therapy (inpatient) Days 103 0.17 0.58 118 0.24 0.69 
Follow-up (post discharge)               
ITU Days 81 0.00 0.00 94 0.03 0.31 
General ward Days 92 2.87 14.37 101 0.86 3.43 
Cardiac ward Days 92 0.40 1.49 100 1.15 4.32 
24 hour BP Monitoring No. of tests 80 0.16 0.56 94 0.19 1.26 
Radiography (chest) No. of tests 80 0.49 0.89 94 0.64 0.90 
Computerised Tomography Scan  No. of tests 80 0.14 0.52 94 0.15 0.51 
Echo TTE No. of tests 80 0.41 0.69 94 0.55 0.84 
Echo TOE No. of tests 80 0.03 0.22 92 0.03 0.18 
Echo Stress No. of tests 80 0.01 0.11 93 0.01 0.10 
24 hour ECG No. of tests 80 0.11 0.39 94 0.15 0.46 
12 hour ECG No. of tests 80 0.69 0.91 94 0.90 1.18 
Exercise Tolerance Test No. of tests 80 0.08 0.27 93 0.06 0.25 
MRI scan No. of tests 79 0.03 0.16 94 0.05 0.23 
Full Pulmonary Function Testing  No. of tests 80 0.05 0.22 94 0.03 0.18 
Blood test No. of tests 81 0.05 0.22 94 0.06 0.35 
A&E visit No. of visits 80 0.09 0.28 94 0.22 0.51 
Arrhythmia clinic No. of visits 80 0.03 0.16 94 0.00 0.00 
Cardiac Rehabilitation No. of visits 79 0.84 2.76 93 0.32 1.43 
Cardio Clinic No. of visits 79 0.48 0.68 94 0.49 0.73 
GP Home Visits No. of visits 79 0.23 0.64 94 0.30 0.75 
GP Visits No. of visits 80 2.00 2.34 94 2.20 2.31 
Nurse (Specialist Community) Home 
Visits 
No. of visits 80 0.31 1.12 94 0.39 1.18 
Nurse (GP Practice) Visits No. of visits 80 2.10 10.02 92 0.75 1.46 
Occupational therapy (outpatient) No. of visits 80 0.11 0.71 94 0.06 0.62 
Pacemaker No. of visits 79 0.08 0.68 93 0.06 0.38 
Physiotherapy (home) No. of visits 80 0.05 0.35 94 0.00 0.00 
Physiotherapy (outpatient) No. of visits 80 0.04 0.19 94 0.01 0.10 
Wound clinic No. of visits 80 0.06 0.29 94 0.02 0.15 
*discharged to convalescence/long term care/acute hospital instead of home 
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Drugs: Drug use was matched to a corresponding unit cost using the NHS Electronic Drug tariff [5] and BNF 
[6] to sum costs across drug type for each patient.  
 
Information on drugs administered during the primary admission was complete, with total amount of each drug 
per patient checked against patient prescriptions. However drug use post-discharge was self-reported and it was 
not possible to verify or retrieve any further data on this over the follow-up period.  
 
Health State Utilities: This data was collected using EQ-5D-3L and SF-36 questionnaires. EQ-5D-3L responses 
were converted to utility values using Dolan et al (1995) [7] and to quality-adjusted life years (QALYs) for the 
trial period using the area under the curve method. SF-36 data was mapped to SF-6D utility values based on the 
ScHARR (School of Health and Related Research, University of Sheffield) algorithm and were converted to 
QALY scores (Brazier et al 2002 [8]). A value of 0 was assigned from date of death. 
 
 
Missing data 
The patterns of missing data for resource use and utilities were tested using Pearson Chi square goodness of fit 
and Wilcoxon rank sum tests for being missing at random and completely at random using the following 
variables: age, sex, treatment and health status at baseline (EQ-5D).  The baseline characteristics assessed were 
not statistically significantly different between the two groups and multiple imputations were used for economic 
analysis. Patients were assigned zero cost and zero utility value from point of death. 
 
Hospital stay: For primary admission, there were a few item non-responses for resource use data but no 
censored data. Complete information was available on all respondents barring one participant who withdrew 
from the trial after operation.  
 
Post-discharge: The frequency of missing data for resource use after discharge is provided in Table B3 for the 
two groups. Imputation models did not converge at month twelve and resource use was aggregated over time, 
i.e. imputation was carried out for the aggregate value for each item rather than at each time period. The 
proportion of missing values in the aggregated utility data ranged from 11% to 25% in resource use post 
discharge (Table B3).  
 
Table B3. Missing follow-up resource use 
 
Follow up Resource Use Full Sternotomy   Mini-sternotomy Total 
6 weeks 
  
  
Missing 3 4 7 
Lost to follow up 4 6 10 
Dead 1 4 5 
Observations 96 104 200 
6 months 
  
  
Missing 2 5 7 
Lost to follow up 8 9 17 
Dead 2 6 8 
Observations 92 98 190 
12 months 
  
  
Missing 9 4 13 
Lost to follow up 11 13 24 
Dead 4 7 11 
Observations 80 94 174 
Total 104 118 222 
 
 
Drugs: Only drugs taken from randomisation to 12 month follow up period were accounted for (covering 3,078 
drug uses of 118 different drugs). A number of assumptions (about quantity/dose and length of administration) 
were used to minimise the degree of missing information on drugs used.  For example, when dosage or 
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frequency of dose per day was missing, the mode usage among trial participants was used or, if not available, 
the BNF dosage was used. Duration of medicinal use was calculated using start and stop dates for drugs used in 
primary admission and follow-XS+RZHYHUZKHQVWDUWVWRSGDWHVZHUHPLVVLQJUHSOLHVWRD³\HVQR´TXHVWLRQ
on use of drugs at follow-up time points informed duration.  For example if a drug was taken during inpatient 
stay, 6 week, 6 month and 12 month follow up, the drug was said to be used for entire 12 month trial period. 
However further assumptions about duration of medication were used when data was less forthcoming; for 
example drugs which were being taken only at 12 month follow up, without start date or stop date specified, 
were assumed to have been taken according to prescription every day for an average of three months (based on 
expert consultation). 58 records had insufficient information on usage for such personalised manual imputation, 
requiring predictive mean matching (conditioned on patient ID and name of drug).   
 
Health State Utilities: EQ-5D-3L and SF-6D utility data were imputed at each follow-up as presented in Table 
B4, and percent of missing value ranged from 9% to 23%. Further breakdown of missing data for resource use 
and HRQoL questionnaires, and imputation required for each variable is provided in Table B4. 
 
 
Table B4. Incomplete data and imputation 
  Full Sternotomy Mini-sternotomy 
Resource Use 
Comple
te 
Incompl
ete Imputed Total 
Comple
te 
Incompl
ete Imputed Total 
Primary admission         
Theatre time (minutes) 104 0 0 104 118 0 0 118 
Critical care stay (hours) 103 1 1 104 118 0 0 118 
Cardiac ward stay (days) 103 1 1 104 118 0 0 118 
Rehabilitation days*  103 1 1 104 117 1 1 118 
Acute hospital days* 103 1 1 104 117 1 1 118 
Physiotherapy visits  103 1 1 104 117 1 1 118 
Occupational therapy visits  103 1 1 104 118 0 0 118 
Follow-up (post discharge)         
Post discharge ITU days  81 23 23 104 94 24 24 118 
Post discharge general ward stay 92 12 12 104 101 17 17 118 
Post discharge cardiac ward stay 92 12 12 104 100 18 18 118 
24 hour BP Monitoring 80 24 24 104 94 24 24 118 
Radiography (chest) 80 24 24 104 94 24 24 118 
Computerised Tomography Scan  80 24 24 104 94 24 24 118 
Echo TTE 80 24 24 104 94 24 24 118 
Echo TOE 80 24 24 104 92 26 26 118 
Echo Stress 80 24 24 104 93 25 25 118 
24 hour ECG 80 24 24 104 94 24 24 118 
12 hour ECG 80 24 24 104 94 24 24 118 
Exercise Tolerance Test 80 24 24 104 93 25 25 118 
MRI scan 79 25 25 104 94 24 24 118 
Pulmonary Function Testing  80 24 24 104 94 24 24 118 
Blood test 81 23 23 104 94 24 24 118 
A&E visit 80 24 24 104 94 24 24 118 
Arrhythmia clinic 80 24 24 104 94 24 24 118 
Cardiac Rehabilitation 79 25 25 104 93 25 25 118 
Cardio Clinic 79 25 25 104 94 24 24 118 
GP Home Visits 79 25 25 104 94 24 24 118 
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GP Visits 80 24 24 104 94 24 24 118 
Nurse (Specialist Community) 
Home Visits 
80 24 24 104 94 24 24 118 
Nurse (GP Practice) Visits 80 24 24 104 92 26 26 118 
Occupational therapy  80 24 24 104 94 24 24 118 
Pacemaker 79 25 25 104 93 25 25 118 
Physiotherapy (home) 80 24 24 104 94 24 24 118 
Physiotherapy 80 24 24 104 94 24 24 118 
Wound clinic 80 24 24 104 94 24 24 118 
EQ-5D Score         
Baseline  95 9 9 104 105 13 13 118 
4 Days Post Operation 89 15 15 104 92 26 26 118 
Discharge 88 16 16 104 103 15 15 118 
6 weeks follow-up 88 16 16 104 106 12 12 118 
6 months follow-up 95 9 9 104 105 13 13 118 
12 months follow-up 84 20 20 104 103 15 15 118 
SF-6D Score         
Baseline  89 15 15 104 101 17 17 118 
6 weeks follow-up 88 16 16 104 102 16 16 118 
6 months follow-up 90 14 14 104 102 16 16 118 
12 months follow-up 82 22 22 104 91 27 27 118 
 
 
Imputation 
Missing values were imputed conditional on sex, age, type of replacement valve used, risk classification 
measured using New York Heart Association (NYHA) Functional Classification and Canadian Cardiovascular 
Society (CCS) grading of angina. To avoid loss in efficiency, missing values for resource use and utility values 
at different time points were replaced using multiple imputations by chained equations.  
 
Chained predictive mean matching was used to replace missing data for resource use and quality of life 
variables, and a total of 20 imputed datasets were created, stratified by treatment group. The imputed resource 
use is summarised in Table B5. However while conducting probabilistic analysis using bootstrap method; 
multiple imputation was carried out only once for each iteration with a total of 1000 iterations to adequately 
retain between imputation variance. The distribution of imputed values was visually checked for comparability 
with the observed data.  
 
Table B5. Summary of resource use  
 
  Full Sternotomy Mini-sternotomy 
Primary Admission Costs Unit of 
measurement 
Obs Mean 
resource use/ 
patient 
SD Obs Mean resource 
use/ 
patient 
SD 
Theatre 
Minutes 104 191.19 62.15 118 221.11 102.65 
Critical care (ITU) 
Hours 104 34.52 56.91 118 55.24 94.69 
Cardiac ward  
Days 104 7.07 4.29 118 6.90 3.87 
Rehabilitation*  
Days 104 2.42 11.84 118 1.66 10.22 
Acute hospital* 
Days 104 0.89 4.95 118 0.77 5.08 
Physiotherapy (inpatient) 
Days 104 5.88 4.20 118 5.94 5.15 
Occupational therapy (inpatient) 
Days 104 0.17 0.58 118 0.24 0.69 
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Follow-up (post discharge)  
            
ITU 
Days 104 0.00 0.00 118 0.03 0.28 
General ward 
Days 104 2.61 13.55 118 0.77 3.20 
Cardiac ward 
Days 104 0.38 1.43 118 1.19 4.14 
24 hour BP Monitoring No. tests 
104 0.18 0.52 118 0.17 1.13 
Radiography (chest) No. tests 
104 0.55 0.87 118 0.61 0.83 
CT Scan  No. tests 
104 0.16 0.48 118 0.16 0.49 
Echo TTE No. tests 
104 0.42 0.66 118 0.56 0.79 
Echo TOE No. tests 
104 0.02 0.20 118 0.05 0.19 
Echo Stress No. tests 
104 0.01 0.10 118 0.01 0.09 
24 hour ECG No. tests 
104 0.13 0.41 118 0.16 0.44 
12 hour ECG No. tests 
104 0.72 0.85 118 0.94 1.17 
Exercise Tolerance Test No. tests 
104 0.07 0.24 118 0.06 0.23 
MRI scan 
No. tests 104 0.02 0.15 118 0.06 0.22 
Full Pulmonary Function Testing 
No. tests 104 0.06 0.22 118 0.03 0.16 
Blood test 
No. tests 104 0.06 0.21 118 0.07 0.33 
A&E visit 
No. visits 104 0.13 0.31 118 0.24 0.50 
Arrhythmia clinic 
No. visits 104 0.02 0.14 118 0.00 0.00 
Cardiac Rehabilitation 
No. visits 104 1.07 2.78 118 0.34 1.36 
Cardio Clinic 
No. visits 104 0.47 0.62 118 0.52 0.72 
GP Home Visits 
No. visits 104 0.27 0.64 118 0.25 0.68 
GP Visits 
No. visits 104 2.00 2.16 118 2.17 2.18 
Nurse (Specialist Community) 
Home Visits No. visits 104 0.38 1.06 118 0.47 1.22 
Nurse (GP Practice) Visits 
No. visits 104 1.93 8.83 118 0.71 1.32 
Occupational therapy  
No. visits 104 0.15 0.70 118 0.05 0.55 
Pacemaker 
No. visits 104 0.06 0.59 118 0.08 0.39 
Physiotherapy (home) 
No. visits 104 0.05 0.32 118 0.00 0.00 
Physiotherapy  
No. visits 104 0.05 0.20 118 0.02 0.11 
Wound clinic 
No. visits 104 0.06 0.28 118 0.03 0.15 
*discharged to convalescence/long term care/acute hospital instead of home 
 
 
Adjustment method 
 
To account for differences in baseline utility values, as well as skewness, censoring and confounding in cost 
data, linear regression models were used to provide adjusted estimates of mean values.  Control variables used 
were age, sex, valve, EQ-5D-3L baseline value and treatment arm. The type of valve used for replacement was 
also controlled for, because it was used as a stratification factor in the randomisation.  
 
Incremental cost effectiveness analysis and sensitivity analyses 
 
Differences in estimated costs and EQ-5D QALYs between trial arms, using raw data with imputation, were 
tested using two-sample t-test with equal variances.   
 
Incremental cost-effectiveness ratios were also constructed using adjusted mean estimates of costs and QALYs 
XVLQJµVHHPLQJO\XQUHODWHGUHJUHVVLRQ¶WRDFFRXQWIRUFRUUHODWLRQEHWZHHQFRVWVDQGHIIHFWVDWWKHSDWLHQW-level.  
This regression technique relies on the multivariate normality of the group-specific mean costs and QALYs, and 
is valid where the individual costs and QALYs are skewed (Faria et al 2014, [9]). 
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Probabilistic Sensitivity Analysis (PSA) was used to characterise the uncertainty of input parameters and a 
bootstrap approach (with 1000 bootstrapped samples) was applied to estimate the precision of results. The 
probability that mini-sternotomy is cost-effective when compared to full sternotomy is presented, at varying 
willingness to pay (WTP) threshold values, using a Cost Effectiveness Acceptability Curve (CEAC) and 
incremental net monetary benefit. 
 
Deterministic sensitivity analyses and scenario analysis were used to explore the robustness of cost-
effectiveness results that adopted different methodological approaches or assumptions (see Table B6). Baseline 
characteristics were assessed using Chi square and rank sum test, to assess whether patients included in the 
complete case analysis were different from those outside the complete case analysis. 
 
 
Table B6. Summary of deterministic sensitivity and scenario analyses undertaken 
 
Sensitivity analyses Rationale  
 
1. Complete case analysis 
 
Only including respondents with no missing values across all variables and 
across follow-up; to check results in sample requiring no missing value 
imputation 
 
2. Excluding patients who died during primary 
admission 
Patients who died during primary admission were the main cost driver and 
required substantial surgical time and cardiac care; to assess whether excluding 
these patients would change recommendations. 
 
3. Excluding additional equipment cost required Assuming the additional equipment required for the surgeries already exists in 
the trusts;  
 
4. Excluding follow-up resource use To test the assumption that the cost difference between the two arms were 
accrued during primary admission, to allow comparison with literature that 
missed these costs, but still retain benefits as captured in other studies. 
 
5. Excluding follow-up resource use and utility data Data up to discharge had few missing values; also to assess impact of having a 
shorter cut-off time point for trial (as wider literature had) but provide a less 
biased analysis that measures benefits but not costs. 
 
6. Use SF-6D utility values  
 
SF-6D values used as an alternative construction for QALYs 
 
 
Results 
 
The comparison of mean costs per patient up to one year (see Table B7), using raw data with imputation, shows 
that mini-sternotomy was £1,714 more than median sternotomy although this was not statistically significant.  
The higher costs resulted from longer surgery time, additional equipment and longer time in critical care. EQ-
5D QALYs were very slightly higher in the mini-sternotomy arm compared with full sternotomy (difference 
0.0279), but this was not statistically significantly so (see Table B8), and there was no statistically significant 
difference in SF6D QALYs either.  Figures B1 and B2 illustrate the distribution of total costs and QALYs across 
the patients in the trial.  
 
Table B9 summarises the comparison of costs and QALYs. The additional cost of gaining an additional QALY 
using mini-sternotomy rather than median sternotomy when imputed using PMM method is £61,379 and the net 
monetary loss at a willingness to pay (WTP) of £20,000 is £1,155.  
 
Seemingly unrelated regression analysis of costs and QALYs, adjusted for baseline characteristics showed that, 
in terms of QALYS, mini-sternotomy was not statistically significantly different from full sternotomy. Table 
B10 also shows that the coefficient for cost was positive, indicating mini-sternotomy was more costly than full 
sternotomy and that this difference was statistically significant.  Mini-sternotomy is therefore dominated by 
median sternotomy.  The cost effectiveness plane for the analysis is illustrated in Figure B3. 
 
The probabilistic sensitivity analysis shows (see Figure B4) that, at a WTP per QALY of £20,000, there is a 
3.7% likelihood that mini-sternotomy is cost-effective compared with median sternotomy and that this 
likelihood rises to 5.1% at a WTP of £30,000/QALY.  The net monetary benefit of mini-sternotomy is negative 
across all WTP threshold values (Figure B5). 
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Deterministic sensitivity analyses (see Table B11) showed that mini-sternotomy was either dominated or had a 
huge ICER. The one exception to this was the complete case analysis (CCA-cost-effectiveness), which found 
mini-sternotomy to be cost-effective. The intervention cost less but also had slightly worse outcomes in this 
sample size, which was limited to only 90 cases. The result indicates a saving of £10,000 for a loss of one 
QALY. The sample is not representative of those with missing data and consisted a larger proportion of females 
than the sample outside the CCA-cost-effectiveness sample. The sensitivity analyses conducted using PSA 
(Table B12) consistently found full sternotomy to be a superior intervention to mini-sternotomy. The cost 
effectiveness planes for the sensitivity analyses are illustrated in Figure B6.  
 
 
Table B7: Comparison of mean costs (SD) per patient up to 12 months post-randomisation (with 
imputation) (UK pounds, 2015) 
 
  
  Full Sternotomy Mini-sternotomy 
Mean 
Unit cost Obs 
Mean 
cost/ 
patient SD Obs 
Mean 
cost/ 
patient SD 
Primary Admission Costs 
Additional surgical items               
Horizontal surgical saw £3,138.2 104 £0.0 £0.0 118 £3.1 £0.0 
Single use saw blade for mini-sternotomy £48.0 104 £0.0 £0.0 118 £48.0 £0.0 
Single use saw blade for full sternotomy £15.8 104 £15.8 £0.0 118 £0.0 £0.0 
Paediatric internal cardioversion paddles £161.7 104 £0.0 £0.0 118 £0.2 £0.0 
Reprocessing cost of defibrillator paddles for each surgery £2.4 104 £2.4 £0.0 118 £2.4 £0.0 
Internal paddle handle £670.0 104 £0.0 £0.0 118 £0.7 £0.0 
Cost of additional surgical items**   104 £16.52 £0.0 118 £52.0 £0.0 
Theatre £20.0 104 £3,823.8 £1,243.0 118 £4,422.2 £2,053.0 
Critical care (ITU) £1,274.9 104 £1,833.8 £3,023.2 118 £2,934.2 £5,029.9 
Cardiac ward £388.0 104 £2,743.7 £1,664.0 118 £2,676.3 £1,499.9 
Rehabilitation* £158.6 104 £384.2 £1,877.6 118 £263.4 £1,621.3 
Acute hospital* £388.0 104 £346.9 £1,918.9 118 £297.5 £1,971.3 
Physiotherapy (inpatient) £12.7 104 £74.5 £53.2 118 £75.2 £65.3 
Occupational therapy (inpatient) £12.7 104 £2.1 £7.3 118 £3.0 £8.7 
Subtotal (primary admission) - 104 £9225.7 £6510.8 118 £10723.9 £8850.2 
Post Primary Admission Costs 
Hospital Admission           
 
  
ITU £1,274.9 104 £0.0 £0.0 118 £32.4 £352.1 
General ward £103.0 104 £268.4 £1,395.4 118 £79.4 £329.5 
Cardiac ward £388.0 104 £149.2 £554.8 118 £463.6 £1,606.4 
Tests           
 
  
24 hour Blood Pressure Monitoring £61.5 104 £10.9 £32.0 118 £10.2 £69.5 
Radiography (chest) £3.5 104 £19.4 £30.9 118 £21.6 £29.5 
Computerised Tomography Scan  £122.3 104 £19.4 £58.6 118 £19.7 £59.8 
Echo TTE £83.9 104 £35.1 £55.2 118 £46.9 £66.6 
Echo TOE £128.5 104 £2.5 £25.2 118 £6.5 £24.3 
Echo Stress £128.5 104 £1.2 £12.6 118 £1.1 £11.8 
24 hour ECG £140.7 104 £18.3 £57.2 118 £22.7 £62.3 
12 hour ECG £140.7 104 £101.5 £119.6 118 £132.9 £165.0 
Exercise Tolerance Test £140.7 104 £9.5 £34.0 118 £8.9 £32.6 
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MRI scan £146.2 104 £3.5 £21.3 118 £9.3 £32.5 
Full Pulmonary Function Testing  £55.3 104 £3.2 £12.4 118 £1.6 £9.1 
Blood test £3.5 104 £0.0 £0.1 118 £0.0 £0.1 
Healthcare visits               
A&E visit £140.6 104 £18.9 £43.0 118 £33.4 £70.4 
Arrhythmia clinic £131.1 104 £2.5 £18.1 118 £0.0 £0.0 
Cardiac Rehabilitation £97.8 104 £104.4 £271.9 118 £33.6 £133.4 
Cardio Clinic £123.0 104 £57.4 £76.3 118 £63.6 £88.1 
GP Home Visits £45.0 104 £12.1 £28.9 118 £11.3 £30.4 
GP Visits £65.0 104 £129.7 £140.6 118 £141.3 £141.8 
Nurse (Specialist Community) Home Visits £19.4 104 £7.3 £20.6 118 £9.0 £23.6 
Nurse (GP Practice) Visits £14.5 104 £28.0 £127.7 118 £10.3 £19.2 
Occupational therapy (outpatient) £16.7 104 £2.5 £11.7 118 £0.8 £9.2 
Pacemaker £76.3 104 £4.4 £44.9 118 £6.1 £29.5 
Physiotherapy (home) £27.0 104 £1.4 £8.6 118 £0.0 £0.0 
Physiotherapy (outpatient) £16.1 104 £0.8 £3.4 118 £0.3 £1.9 
Wound clinic £54.9 104 £3.4 £15.2 118 £1.6 £8.3 
Subtotal (post-primary admission) - 104 £1014.9 £1777.5 118 £1168.2 £2077.9 
Drugs (total) - 104 £379.4 £548.2 118 £441.4 £976.7 
Total cost   104 £10,620.0 £7,623.8 118 £12,333.5 £9,864.2 
*discharged to convalescence/long term care/acute hospital instead of home 
**mean cost per patient estimated by assuming that the saw, paddle and handle have a twenty year life span and 
are used in 255 surgeries in every 5 years; NB: defib (paddle, handle and sterilisation cost) applicable in only 
30% of cases 
 
 
Table B8. Summary of utility values and QALYs  
 
  Full Sternotomy Mini-sternotomy 
EQ-5D Obs Mean Utility SD Obs Mean Utility SD 
Baseline  
104 0.6988 0.24 118 0.7793 0.18 
4 Days Post Operation 
104 0.3721 0.29 118 0.4430 0.28 
Discharge 
104 0.5815 0.23 118 0.5940 0.25 
6 weeks follow-up 
104 0.6930 0.21 118 0.7195 0.24 
6 months follow-up 
104 0.8272 0.22 118 0.8322 0.24 
12 months follow-up 
104 0.7584 0.29 118 0.8253 0.29 
EQ-5D QALYs 
104 0.7699 0.19 118 0.7978 0.21 
   
  Full Sternotomy Mini-sternotomy 
SF-6D Obs Mean Utility SD Obs Mean Utility SD 
Baseline  
104 0.6418 0.11 118 0.6802 0.12 
6 weeks follow-up 
104 0.6327 0.10 118 0.6356 0.14 
6 months follow-up 
104 0.7184 0.16 118 0.7332 0.19 
12 months follow-up 
104 0.6868 0.19 118 0.7058 0.23 
SF-6D QALYs 
104 0.6847 0.12 118 0.6989 0.16 
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Figure B1. Distribution of total cost 
 
 
 
 
Figure B2. Distribution of QALYs 
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Table B9. Comparison of costs and QALYS (raw data, with imputation)  
 
 
Full Sternotomy (n=104) Mini-sternotomy (n=114) 
 
Mean SD Mean SD 
Total costs over 12 months 
£10,620 £7,624 £12,334 £9,864 
Incremental cost at 12 months (MS-FS) - £1,714 
 
Total EQ5D3L QALYs 
0.7699 0.19 0.7978 0.21 
Incremental EQ5D3L QALYs (MS-FS) - 0.0279   
ICER - £61,379 
INMB at WTP of £20,000/QALY - -£1,155 
INMB at WTP of £30,000/QALY - -£876 
 
 
Table B10. Regression estimates of costs and QALYs 
 
Dependant variable:  EQ5D QALYs 
  Coefficient Std. Err. P value [95% Conf. Interval] 
Mini-sternotomy -0.0040 0.0245 0.87 -0.0520 0.0440 
Male 0.0250 0.0246 0.31 -0.0231 0.0732 
Age -0.0051 0.0014 0.00 -0.0078 -0.0024 
Baseline EQ-5D score 0.3037 0.0590 0.00 0.1880 0.4194 
Tissue valve 0.0794 0.0459 0.08 -0.0107 0.1694 
Constant 0.7391 0.1093 0.00 0.5249 0.9533 
Dependant variable:  Total Cost (£) 
  Coefficient Std. Err. P value [95% Conf. Interval] 
Mini-sternotomy 2010.22 1201.57 0.09 -344.82 4365.25 
Male -1275.52 1205.23 0.29 -3637.73 1086.70 
Age 98.32 67.58 0.15 -34.13 230.77 
Baseline EQ-5D score -983.50 2896.40 0.73 -6660.34 4693.33 
Tissue valve -853.43 2254.14 0.71 -5271.45 3564.60 
Constant 5704.71 5362.01 0.29 -4804.64 16214.06 
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Table B11. Deterministic sensitivity analysis (using difference MS - FS, adjusted for baseline)  
 
 
Obs 
Incremental cost 
over 12 months  
(MS-FS) 
Incremental QALYs 
over 12 months  
(MS-FS) 
ICER 
INMB at 
£20,000 
per QALY 
INMB at 
£30,000 per 
QALY 
Mean 
Std 
Error 
Mean 
Std 
Error 
Missing values imputed by 
PMM  
222 £2,010 £1,202 -0.0040 0.0245 Dominated -£2,089.26 -£2,128.78 
Using SF6D QALYs  222 £2,010 £1,202 -0.0017 0.0178 Dominated -£2,044.44 -£2,061.55 
Assuming there is no 
additional equipment 
required for the two 
procedures 
222 £1,975 £1,202 -0.0040 0.0245 Dominated -£2,053.73 -£2,093.26 
Excluding follow-up 
resource use 
222 £1,664 £1,060 -0.0040 0.0245 Dominated -£1,742.98 -£1,782.50 
Complete case analysis 90 -£150 £661 -0.0145 0.0334 £10,333.62 -£139.89 -£284.60 
Excluding patients who died 
during primary admission 
219 £1,408 £1,128 0.0172 0.0216 £81,905.62 -£1,064.40 -£892.46 
Including costs and QALY 
data only up to discharge 
222 £1,664 £1,060 0.0013 0.0009 £1,316,409.02 -£1,638.66 -£1,626.02 
 
Table B12. Probabilistic sensitivity analysis (using difference MS - FS, adjusted for baseline)  
 
 
Obs 
Incremental cost 
over 12 months  
(MS-FS) 
Incremental 
QALYs over 12 
months  
(MS-FS) ICER 
INMB at 
£20000 
INMB at 
£30000 
Mean 
Std 
Error 
Mean 
Std 
Error 
Missing values imputed by PMM 
and adjusted 
1000 £2,154 £36 -0.0122 0.0008 Dominated -£2,396.99 -£2,518.59 
Using SF6D QALYs  1000 £2,154 £36 -0.0075 0.0006 Dominated -£2,303.03 -£2,377.66 
Assuming there is no additional 
equipment required for the two 
procedures 
1000 £2,245 £40 -0.0096 0.0008 Dominated -£2,437.25 -£2,533.50 
Excluding follow-up resource use 1000 £1,835 £35 -0.0131 0.0008 Dominated -£2,096.58 -£2,227.15 
Complete case analysis 1000 -£111 £22 -0.0121 0.0011 £9,170.78 -£130.56 -£251.12 
Excluding patients who died during 
primary admission 
1000 £1,433 £32 0.0147 0.0007 £97,425.25 -£1,138.55 -£991.50 
Including costs and QALY data 
only up to discharge 
1000 £1,835 £35 0.0008 0.0000 £2,415,384.92 -£1,820.25 -£1,812.65 
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Figure B3. Cost effectiveness plane (using difference MS-FS, adjusted for baseline) 
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Figure B4. Cost-effectiveness acceptability curve (EQ-5D) 
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Figure B5. Net monetary benefit (controlling for baseline characteristics and missing data) 
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Figure B6. Sensitivity analyses using difference (MS - FS), adjusted for baseline 
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